Toxicology – Cadmium Fume Fever/Pneumonitis

Core concept

Acute inhalation of cadmium oxide fumes can initially resemble benign metal fume fever but may progress to severe chemical pneumonitis, noncardiogenic pulmonary edema, ARDS, and respiratory failure.

The characteristic progression is:

Cadmium fume inhalation → latent period → flu-like illness → cough/chest pain/dyspnea → chemical pneumonitis ± pulmonary edema

The key clinical warning is:

A patient may look relatively well immediately after exposure and deteriorate several hours later.

Symptoms commonly begin approximately 4–10 hours after exposure, while severe pulmonary injury can evolve over the following hours to days.

Sources and Uses

Cadmium oxide fumes are generated when cadmium-containing materials are heated.

Important exposure settings include:

• Welding cadmium-plated steel
• Flame cutting cadmium-coated metal
• Brazing
• Silver soldering
• Smelting
• Refining
• Cadmium-alloy production
• Battery manufacture
• Metal reclamation/recycling

OSHA specifically recognizes welding, cutting, brazing, and other work involving cadmium-containing materials as occupational exposure settings.

Cadmium oxide

Cadmium oxide fume is:

• Odorless
• Composed of very fine airborne particles
• Capable of producing significant toxicity before the worker recognizes substantial irritation

Therefore:

Absence of an obvious odor or severe immediate airway irritation does not exclude a dangerous exposure.

Cadmium Fume Fever vs Cadmium Pneumonitis

Metal fume fever-like phase

Early cadmium inhalation can produce:

• Fever
• Chills
• Myalgia
• Headache
• Malaise
• Cough

This may look identical to ordinary metal fume fever.

Cadmium pneumonitis

Unlike typical zinc-associated metal fume fever, which generally resolves spontaneously within approximately 48 hours:

Cadmium inhalation can progress to destructive pulmonary injury.

Patients with more intense cadmium exposure who fail to improve may develop:

Tracheobronchitis → chemical pneumonitis → pulmonary edema → ARDS

ATSDR specifically distinguishes the generally self-limited course of ordinary metal fume fever from cadmium pneumonitis, which may progress between approximately 8 hours and 7 days after exposure.

High-yield distinction

Ordinary metal fume fever → improves within ~24–48 h

Cadmium fume toxicity → worsening dyspnea/infiltrates/hypoxemia = chemical pneumonitis until proven otherwise

Pathophysiology

Cadmium oxide particles deposit in the respiratory tract and cause direct inflammatory and cytotoxic lung injury.

Mechanisms include:

• Oxidative stress
• Glutathione depletion
• Lipid peroxidation
• Inflammatory cytokine release
• Endothelial injury
• Alveolar epithelial injury

Severe pulmonary injury may produce:

• Tracheobronchial hyperemia
• Pulmonary edema
• Intra-alveolar hemorrhage
• Alveolar epithelial injury
• Small-vessel thrombosis
• Fibroblastic proliferation

The result is:

Capillary/alveolar injury → permeability edema → impaired gas exchange → hypoxemic respiratory failure

Toxic Exposure

There is no single airborne concentration that reliably predicts clinical outcome.

Severity depends on:

Concentration × duration of exposure

as well as:

• Particle characteristics
• Respiratory protection
• Ventilation
• Individual susceptibility

Historical human fatalities have occurred after exposures such as:

• Approximately 39 mg Cd/m³ for 20 minutes
• Approximately 40–50 mg/m³ for 1 hour
• Approximately 9 mg/m³ for several hours

These historical observations form part of the basis for the NIOSH IDLH of 9 mg/m³.

Thus, the older statement that 40 mg/m³ is lethal is too simplistic.

Clinical Features

Latent Period

The physical examination immediately after exposure may be normal.

Symptoms are characteristically delayed approximately:

4–10 hours

after significant inhalation.

This delay is a major diagnostic pitfall.

Early / Metal-Fume-Fever-Like Phase

Possible early manifestations include:

• Throat irritation
• Cough
• Headache
• Nausea
• Malaise
• Weakness
• Myalgia
• Chills
• Fever

Vital signs may show:

• Tachycardia
• Tachypnea
• Fever

At this stage the illness may appear deceptively benign.

Progressive Pulmonary Toxicity

Concerning manifestations include:

• Increasing cough
• Dyspnea
• Chest tightness
• Pleuritic chest pain
• Wheezing
• Crackles
• Hypoxemia
• Hemoptysis

Severe exposure may progress to:

• Tracheobronchitis
• Diffuse pulmonary infiltrates
• Noncardiogenic pulmonary edema
• Intra-alveolar hemorrhage
• ARDS
• Respiratory failure

Timing of deterioration

Pulmonary toxicity may continue evolving over:

Hours to several days

and patients who do not improve over the first 1–2 days deserve particular concern for cadmium chemical pneumonitis.

Other Organ Toxicity

Although the lungs dominate acute inhalational poisoning, sufficiently large absorbed doses can also cause:

Renal

• Proximal tubular injury
• Acute kidney injury

Hepatic

• Elevated aminotransferases
• Hepatocellular injury

These are much less characteristic than the pulmonary syndrome but should be considered after substantial exposure.

Diagnosis

Diagnosis is primarily based on:

Compatible occupational exposure + delayed respiratory/flu-like syndrome

A careful occupational history is often more useful than an individual laboratory test.

Ask specifically about:

• What metal was being welded/cut
• Whether it was cadmium plated
• Solder composition
• Duration of work
• Confined-space exposure
• Ventilation
• Respirator use
• Whether coworkers are symptomatic

Material safety documentation or analysis of the metal/fume source can be valuable.

Differential Diagnosis

Other toxic inhalations

Consider:

• Phosgene
• Nitrogen dioxide
• Zinc oxide metal fume fever
• Copper fumes
• Other metal fumes
• Chlorine
• Smoke inhalation

Medical

Consider:

• Influenza or other viral illness
• Pneumonia
• Pulmonary embolism
• Acute heart failure
• Other causes of ARDS

Key diagnostic clue

A welder or metalworker who develops:

Delayed fever + cough + progressive dyspnea after heating cadmium-plated metal

should be considered to have cadmium fume toxicity until adequately evaluated.

Investigations

Pulse Oximetry

Perform in all symptomatic patients.

However:

Normal early oxygen saturation does not exclude evolving pneumonitis.

Serial measurements are more useful than a single initial value.

Chest Radiograph

Obtain for:

• Dyspnea
• Hypoxemia
• Persistent cough
• Chest pain
• Abnormal lung examination

The initial radiograph may be normal early despite significant exposure.

Later findings may include:

• Diffuse infiltrates
• Pulmonary edema
• ARDS pattern

Blood Gas

Consider ABG or VBG when there is:

• Respiratory distress
• Hypoxemia
• Suspected hypercapnia
• Severe systemic illness

Laboratory Tests

For moderate/severe exposure consider:

• CBC
• Electrolytes
• BUN
• Creatinine
• Urinalysis
• Liver enzymes

Blood Cadmium

Blood cadmium may help confirm recent significant exposure, but it should not determine acute pulmonary management.

A single blood cadmium level:

• Does not reliably predict severity
• Does not exclude toxicity when low
• Should not delay treatment

The older threshold of >5 μg/L should therefore not be treated as a definitive acute poisoning cutoff.

Urinary Cadmium

Urinary cadmium is more useful for assessing cumulative occupational body burden than for determining the immediate severity of acute pneumonitis.

It is not an emergency bedside test.

Urinary β₂-Microglobulin

β₂-microglobulin is useful mainly as a marker of:

Chronic proximal tubular cadmium injury

It is not a primary diagnostic test for acute cadmium fume pneumonitis.

This corrects the emphasis in the older source.

Treatment

1. Remove From Exposure

Immediately:

• Stop welding/cutting
• Move the patient to uncontaminated air
• Remove contaminated clothing if necessary

Rescuers must avoid entering a contaminated environment without appropriate respiratory protection.

2. Oxygen

Give supplemental oxygen for:

• Hypoxemia
• Respiratory distress
• Significant pulmonary toxicity

There is no need to automatically administer “100% oxygen” to every asymptomatic patient; oxygen should be titrated according to clinical need.

The mainstay of serious inhalational cadmium treatment remains:

• Oxygen
• Supportive care
• Mechanical ventilation when required

3. Bronchospasm

If bronchospasm occurs:

Inhaled β₂-agonist bronchodilators may be used.

For example:

• Albuterol/salbutamol

Treat according to the patient’s clinical bronchospasm rather than routinely administering bronchodilators to everyone.

4. Pulmonary Edema / ARDS

Severe cadmium pneumonitis is treated similarly to other causes of acute lung injury.

Management may include:

• Supplemental oxygen
• High-flow oxygen when appropriate
• Noninvasive support in carefully selected patients
• Endotracheal intubation for respiratory failure
• Lung-protective mechanical ventilation
• Appropriate PEEP
• Conservative fluid strategy once shock has resolved

ATSDR identifies oxygen and mechanical ventilation as central treatments in severe acute inhalational cadmium toxicity.

Avoid fluid overload

This is principally a permeability lung injury, not a disorder requiring aggressive fluid administration unless the patient is genuinely hypovolemic or shocked.

Excessive fluid may worsen pulmonary edema.

Corticosteroids

Older recommendation

The older source recommends:

Methylprednisolone 1 g IV

based on anecdotal experience.

Current interpretation

There is no established high-quality evidence that corticosteroids prevent cadmium-induced pulmonary edema or improve outcomes.

Therefore:

Routine high-dose corticosteroid therapy is not recommended as established treatment for cadmium pneumonitis.

If steroids are considered in an unusual severe case, this should be individualized with:

• Medical toxicology
• Pulmonary/critical-care consultation

rather than given automatically.

The core treatment remains supportive respiratory care.

Antibiotics

Cadmium pneumonitis is a chemical, not bacterial, pneumonitis.

Therefore:

Do not give prophylactic antibiotics.

Antibiotics are indicated only when there is evidence of:

• Secondary bacterial pneumonia
• Another documented infectious process

Antidote

There is no specific antidote for cadmium fume poisoning.

Chelation

Routine chelation is not recommended

The historical suggestion that early CaNa₂EDTA might improve acute cadmium inhalation is not supported by adequate clinical evidence.

Modern ATSDR guidance states that:

Chelation has no established role in cadmium poisoning.

Chelators may mobilize cadmium and potentially increase delivery to the kidney.

Therefore:

Do not routinely administer CaNa₂EDTA for cadmium fume pneumonitis.

Dimercaprol

Dimercaprol (BAL) should not be used for cadmium toxicity because cadmium-chelator complexes can worsen renal injury.

The absence of a proven chelator is an important difference from poisoning by metals such as arsenic or mercury.

Hemodialysis

Hemodialysis is not effective for removing established cadmium body burden because absorbed cadmium becomes strongly protein- and tissue-bound.

Dialysis should therefore not be used simply to treat the cadmium exposure.

It remains appropriate for conventional complications of severe acute kidney injury, such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Fluid overload
• Uremia

Skin and Eye Exposure

If particulate contamination also occurred:

Skin

• Remove contaminated clothing
• Wash thoroughly with soap and water

Eyes

• Irrigate copiously with water or saline

This prevents continued local exposure but does not alter cadmium already deposited in the lungs.

Monitoring

Respiratory

Monitor:

• Respiratory rate
• Work of breathing
• Pulse oximetry
• Serial lung examination

For significant exposure consider:

• Serial chest imaging
• Blood gases
• Continuous cardiac/respiratory monitoring

Renal

After substantial exposure monitor:

• Creatinine
• Electrolytes
• Urine output
• Urinalysis

Hepatic

Consider serial liver tests after substantial systemic exposure.

Observation

The historical fixed rule of:

“12 hours and normal pulmonary function tests = discharge”

should not be applied rigidly.

Because clinically significant symptoms are frequently delayed 4–10 hours, observation after a meaningful exposure should extend through the expected latent period and be individualized according to:

• Exposure magnitude
• Confined-space exposure
• Respiratory protection
• Symptoms
• Examination
• Oxygenation
• Imaging

A patient with a credible substantial exposure should not be discharged simply because the initial examination and chest radiograph are normal.

Admission

Hospital admission is appropriate for:

• Dyspnea
• Persistent cough after substantial exposure
• Chest pain
• Hypoxemia
• Hemoptysis
• Bronchospasm
• Abnormal chest imaging
• Pulmonary edema
• Significant systemic toxicity
• Acute kidney or hepatic injury

Patients with:

• Progressive hypoxemia
• Pulmonary edema
• ARDS
• Respiratory fatigue

require ICU-level care.

Pulmonary Function Testing

PFTs are not required emergently in every exposed patient.

They may be useful for:

• Persistent respiratory symptoms
• Occupational evaluation
• Long-term follow-up after significant pneumonitis

Acute testing should never delay treatment of respiratory distress.

Prognosis

Mild exposure

Patients with a mild metal-fume-fever-like syndrome may recover completely.

Severe pneumonitis

Severe disease may progress over several days and can result in:

• Prolonged respiratory failure
• ARDS
• Pulmonary fibrosis
• Persistent restrictive impairment
• Death

Historical reports documented substantial mortality among patients who developed severe pulmonary edema, but the older statement that approximately 20% of all cadmium fume cases are fatal should not be generalized to contemporary exposures. Severe high-dose occupational exposures are now uncommon.

Persistent pulmonary-function abnormalities have been documented years after severe cadmium pneumonitis.

Long-Term Follow-Up

After significant pneumonitis consider follow-up with:

• Pulmonary function testing
• Respiratory symptom assessment
• Occupational medicine evaluation

Because significant systemic cadmium absorption may also affect the kidneys, follow:

• Creatinine
• Urinalysis
• Occupational cadmium biomarkers when appropriate

Return to cadmium exposure should occur only after occupational safety review and adequate exposure controls.

Occupational Standards

OSHA PEL

Current OSHA permissible exposure limit for cadmium:

5 μg/m³ (0.005 mg/m³) as an 8-hour TWA

OSHA Action Level

2.5 μg/m³ (0.0025 mg/m³) as an 8-hour TWA

NIOSH

NIOSH treats cadmium as an occupational carcinogen and recommends reducing exposure to the lowest feasible concentration.

NIOSH IDLH

For cadmium fume:

9 mg Cd/m³

The difference between these values is important:

OSHA PEL = routine occupational limit

IDLH = immediately dangerous exposure

Prevention

Cadmium fume poisoning is largely preventable.

Important controls include:

• Identifying cadmium-containing metals before heating
• Local exhaust ventilation
• Appropriate respiratory protection
• Avoiding welding/cutting cadmium materials in poorly ventilated spaces
• Occupational air monitoring
• Worker education

Personal protective equipment must complement rather than replace appropriate engineering controls.

Important Pitfalls

1. Calling it ordinary metal fume fever

Early symptoms may be identical.

But:

Worsening after 24–48 h strongly suggests cadmium pneumonitis rather than uncomplicated metal fume fever.

2. Being reassured by an initially normal examination

Cadmium pulmonary toxicity is characteristically delayed.

Symptoms often begin 4–10 hours later.

3. Being reassured by an initially normal chest X-ray

Radiographic pulmonary edema may lag behind the exposure and early symptoms.

Clinical monitoring is essential.

4. Waiting for a cadmium concentration

Blood and urine cadmium testing can support exposure assessment but:

Treatment should never wait for the level.

5. Treating β₂-microglobulin as an acute pneumonitis marker

It is mainly a biomarker of renal tubular injury/chronic cadmium exposure.

6. Giving prophylactic antibiotics

Cadmium pneumonitis is initially a chemical lung injury.

7. Routinely giving megadose steroids

The older recommendation for 1 g methylprednisolone is based on anecdotal experience and is not established evidence-based therapy.

8. Routinely giving EDTA

Modern toxicology does not recommend routine chelation for cadmium poisoning.

9. Assuming dialysis removes cadmium

Dialysis treats complications of renal failure but does not effectively remove tissue-bound cadmium.

10. Using the old workplace limits

Current OSHA PEL:

0.005 mg/m³

Current NIOSH IDLH:

9 mg/m³

High-Yield Toxicology Pearls

Cadmium fume = delayed toxic lung injury

Think:

Welder + cadmium-plated metal + delayed fever/cough → watch for pneumonitis

Key points:

• Cadmium oxide fumes are produced by welding, cutting, brazing, and heating cadmium-containing metals
• Cadmium oxide is odorless
• Initial examination may be normal
• Symptoms typically begin after a 4–10-hour latent period
• Early symptoms can mimic metal fume fever
• Ordinary metal fume fever usually resolves within ~48 hours
• Cadmium toxicity may instead progress to chemical pneumonitis
• Severe toxicity → noncardiogenic pulmonary edema/ARDS
• Main treatment: supportive respiratory care
• Oxygen for hypoxemia
• Bronchodilators for bronchospasm
• Severe cases require lung-protective mechanical ventilation + PEEP
• No specific antidote
• Routine EDTA chelation is not recommended
• Routine high-dose corticosteroids are not established therapy
• Antibiotics only for documented secondary infection
• Blood/urine cadmium concentrations support diagnosis but do not determine acute treatment
• β₂-microglobulin is primarily a renal/chronic exposure biomarker
• Do not rely on a fixed 12-hour discharge rule after substantial exposure
• OSHA PEL: 5 μg/m³ over 8 hours
• OSHA action level: 2.5 μg/m³
• NIOSH IDLH: 9 mg/m³
• Persistent restrictive pulmonary impairment can follow severe pneumonitis
• The most important clinical pearl:

A “metal fume fever” syndrome that worsens rather than improves should prompt urgent reassessment for cadmium pneumonitis.

Toxicology – Cadmium

Core concept

Cadmium is a cumulative toxic metal that primarily injures the lungs after acute inhalation and the kidneys after chronic exposure.

The major toxic syndromes are:

Acute inhalation → delayed chemical pneumonitis + noncardiogenic pulmonary edema

Acute ingestion → severe gastroenteritis ± hepatic/renal injury

Chronic exposure → proximal renal tubular dysfunction → chronic kidney disease + secondary bone disease

Cadmium is also a human carcinogen (IARC Group 1). Current OSHA and NIOSH resources identify occupational cadmium as a carcinogenic hazard.

Sources and Uses

Important occupational sources include:

• Battery manufacture, particularly nickel-cadmium batteries
• Welding or cutting cadmium-plated/coated metals
• Smelting and refining
• Electroplating
• Metal alloy production
• Pigments, paints, and glazes
• Jewelry work
• Soldering
• Plastics and stabilizers
• Mining

Important nonoccupational sources include:

• Tobacco smoke
• Contaminated food
• Environmental contamination

Smoking significantly increases cadmium body burden.

Routes of Exposure

Inhalation

The most dangerous route for acute occupational poisoning.

Heating cadmium-containing metal can generate:

• Cadmium oxide fumes
• Fine respirable particles

Approximately 10–50% of inhaled cadmium may be absorbed depending on particle size, compound solubility, and exposure circumstances.

Ingestion

Cadmium salts can cause profound local gastrointestinal irritation.

GI absorption is substantially lower than pulmonary absorption, but significant systemic poisoning can still occur after large soluble-salt ingestion.

Dermal

Systemic absorption through intact skin is generally limited.

Toxic Dose

There is no single clinically reliable toxic dose.

Historical reports describe lethal oral exposures to soluble cadmium salts in the range of approximately 30–40 mg, but these values vary widely and should not be used as absolute thresholds.

The older textbook’s use of solution concentration in mg/L is particularly misleading because toxicity depends on:

Concentration × volume ingested = actual dose

as well as:

• Chemical form
• Solubility
• Route
• Duration
• Renal function

For inhalation, clinical severity depends on airborne concentration and duration of exposure.

Pathophysiology

Cadmium is a cumulative toxin.

After absorption it binds to proteins, particularly metallothionein, and accumulates predominantly in:

• Kidneys
• Liver

Its biologic elimination is extremely slow.

Cadmium’s estimated half-life may be:

• 6–38 years in the kidney
• 4–19 years in the liver

Important mechanisms include:

• Oxidative stress
• Glutathione depletion
• Lipid peroxidation
• Inflammatory cytokine production
• Endothelial/cellular injury
• Proximal tubular toxicity

Acute Inhalational Toxicity

Key syndrome

Cadmium fumes → delayed inflammatory lung injury

This is one of the most important features of cadmium poisoning:

The patient may initially appear relatively well.

Symptoms often begin approximately:

4–10 hours after exposure

and can subsequently progress to:

• Chemical pneumonitis
• Pulmonary edema
• Acute hypoxemic respiratory failure

Early symptoms

Initially:

• Throat irritation
• Metallic or unpleasant taste
• Cough
• Headache

Several hours later:

• Fever
• Chills
• Myalgia
• Malaise
• Chest tightness
• Pleuritic chest pain
• Dyspnea
• Tachycardia
• Nausea

The initial illness may resemble metal fume fever.

Important distinction from ordinary metal fume fever

Simple metal fume fever is generally self-limited.

Cadmium exposure may instead progress to:

Chemical pneumonitis → noncardiogenic pulmonary edema → ARDS

Patients who fail to improve over the first 1–2 days require particular concern.

Severe respiratory effects

Possible complications include:

• Bronchospasm
• Hemoptysis
• Diffuse pulmonary infiltrates
• Noncardiogenic pulmonary edema
• ARDS
• Respiratory failure
• Death

Progressive lung injury has been described from several hours to days after exposure.

Acute Oral Toxicity

Cadmium salts are potent GI irritants.

Typical manifestations include:

• Severe nausea
• Vomiting
• Salivation
• Abdominal pain
• Cramping
• Diarrhea
• Tenesmus

Severe exposure may cause:

• Hematemesis
• Hemorrhagic gastroenteritis
• Dehydration
• Hypotension
• Metabolic acidosis

Systemic complications can include:

• Hepatic injury
• Acute tubular injury
• Acute kidney injury

Because vigorous vomiting often occurs, the absorbed fraction may be limited after some acute oral exposures.

Chronic Cadmium Toxicity

Kidney – Primary Target

The hallmark of chronic cadmium toxicity is:

Proximal renal tubular dysfunction

Cadmium accumulates within the renal cortex and damages proximal tubular cells.

Early abnormalities include:

• Low-molecular-weight proteinuria
• β₂-microglobulinuria
• Retinol-binding proteinuria

Later manifestations may include:

• Generalized proteinuria
• Glycosuria despite normal blood glucose
• Aminoaciduria
• Phosphaturia
• Reduced concentrating ability
• Decreased GFR
• Chronic kidney disease

ATSDR identifies urinary low-molecular-weight proteins, particularly β₂-microglobulin, as early indicators of chronic cadmium-related renal injury.

Fanconi-Like Syndrome

Severe proximal tubular dysfunction may resemble Fanconi syndrome:

Proximal tubular injury → urinary phosphate/calcium loss → metabolic bone disease

Bone Toxicity

Chronic cadmium exposure can produce:

• Osteomalacia
• Osteoporosis
• Bone pain
• Pathologic fractures

Bone disease is largely secondary to:

• Renal tubular dysfunction
• Phosphate/calcium wasting
• Altered vitamin D metabolism

Itai-Itai Disease

The classic severe chronic cadmium syndrome is:

Itai-itai disease

characterized by:

• Severe bone pain
• Osteomalacia
• Osteoporosis
• Fragility fractures
• Renal tubular dysfunction

It was historically described in heavily environmentally exposed populations in Japan.

Chronic Pulmonary Effects

Long-term occupational inhalation may contribute to:

• Chronic bronchitis
• Emphysema
• Reduced pulmonary function
• Pulmonary fibrosis

Some severe acute inhalational injuries may also leave permanent pulmonary impairment.

Carcinogenicity

Cadmium is classified as:

IARC Group 1 — carcinogenic to humans

Occupational exposure is associated particularly with lung cancer risk.

Current OSHA resources list cadmium as:

• IARC Group 1
• NIOSH occupational carcinogen
• OSHA carcinogen

Other Clinical Features

Hepatic

Acute high-dose exposure may cause:

• Elevated transaminases
• Hepatocellular injury

Severe hepatic injury is less characteristic than pulmonary or renal toxicity.

Cardiovascular

Severe acute poisoning may produce:

• Tachycardia
• Hypotension
• Shock

Associations between chronic cadmium exposure and hypertension/cardiovascular disease have been investigated, but these findings are less specific than renal toxicity.

HEENT

Chronic occupational exposure has historically been associated with:

• Anosmia
• Yellow discoloration near the gingival margin of teeth

These are not sensitive diagnostic findings.

Neurologic

Acute systemic illness may include:

• Headache
• Weakness
• Malaise

Cadmium does not typically produce a dominant neurologic toxidrome.

Diagnosis

Exposure History

A detailed occupational history is crucial.

Ask specifically about:

• Welding
• Flame cutting
• Brazing
• Battery production
• Electroplating
• Smelting
• Jewelry fabrication
• Cadmium-coated metal
• Pigment manufacture

Also ask:

• Smoking history
• Duration of exposure
• Respiratory protection
• Ventilation
• Whether coworkers developed similar symptoms

Laboratory Assessment

Acute Exposure

For significant acute poisoning consider:

• CBC
• Electrolytes
• Bicarbonate
• BUN
• Creatinine
• Urinalysis
• Liver enzymes
• Blood gas if respiratory toxicity is present

For inhalation:

• Pulse oximetry
• Chest radiograph
• Serial respiratory examination

A chest radiograph may initially be normal despite evolving lung toxicity.

Blood Cadmium

What it means

Blood cadmium primarily reflects relatively recent exposure.

It is particularly useful after:

• Recent occupational exposure
• Acute high-dose exposure

It is less useful as a direct measure of total lifetime cadmium burden.

There is no single blood cadmium concentration that reliably defines clinical poisoning.

Thus, the older simple cutoff such as “>7 μg/L = toxicity” should not be used as an absolute diagnostic threshold.

Urinary Cadmium

What it means

In the absence of established renal damage:

Urinary cadmium more closely reflects cumulative body burden and chronic exposure.

However, once tubular injury is present, urinary cadmium can increase because damaged kidneys release accumulated cadmium, making interpretation more complex.

β₂-Microglobulin

Urinary β₂-microglobulin is a marker of proximal tubular injury.

Elevated urinary β₂-microglobulin may therefore provide evidence of early cadmium nephrotoxicity.

It should be interpreted together with:

• Urinary cadmium
• Blood cadmium
• Renal function
• Occupational history

OSHA Biological Monitoring

For cadmium-exposed workers, current OSHA surveillance uses:

• Urine cadmium (CdU)
• Whole-blood cadmium (CdB)
• Urinary β₂-microglobulin

Values at or below:

• CdU 3 μg/g creatinine
• CdB 5 μg/L whole blood
• β₂-microglobulin 300 μg/g creatinine

fall within OSHA’s lowest monitoring category.

Values above these trigger enhanced occupational medical surveillance and exposure reassessment.

Important

These are:

Occupational surveillance thresholds

—not universal clinical “toxic levels.”

Differential Diagnosis

Acute inhalation

Consider:

• Ordinary metal fume fever
• Irritant gas inhalation
• Nitrogen dioxide
• Phosgene
• Hydrofluoric acid fumes
• Viral respiratory illness
• Pneumonia
• ARDS from another cause

Renal toxicity

Consider:

• Lead
• Mercury
• Other nephrotoxic metals
• Diabetes
• Hypertension
• Medication nephrotoxicity
• Primary Fanconi syndrome
• Interstitial nephritis

Bone disease

Consider:

• Vitamin D deficiency
• Hyperparathyroidism
• Renal osteodystrophy
• Other causes of osteoporosis/osteomalacia

Treatment

1. Remove from Exposure

Immediately terminate exposure.

For inhalational exposure:

• Move to fresh air
• Remove contaminated clothing when appropriate
• Prevent secondary workplace exposure

For chronic occupational toxicity:

Preventing further cadmium exposure is the most important intervention.

Acute Inhalation Management

Treatment is primarily supportive.

Provide:

• Supplemental oxygen
• Bronchodilators if bronchospasm occurs
• Close respiratory monitoring
• Mechanical ventilation when necessary

ATSDR identifies oxygen, fluid management, and mechanical ventilation as the mainstay of severe acute inhalational management.

Pulmonary Edema / ARDS

If respiratory failure develops:

• Use lung-protective mechanical ventilation
• Apply appropriate PEEP
• Manage according to standard ARDS principles
• Avoid unnecessary fluid overload

There is no proven cadmium-specific pulmonary antidote.

Observation

Because significant pulmonary toxicity may be delayed for several hours, patients with meaningful fume exposure should not be reassured solely by an initially normal examination.

Acute Oral Exposure

Mouth / GI

After ingestion:

• Rinse mouth
• Treat vomiting and fluid losses
• Correct electrolytes
• Monitor renal and hepatic function after significant exposure

Do Not Induce Vomiting

Ipecac-induced emesis is obsolete and should not be used.

Activated Charcoal

Activated charcoal has not been shown to be reliably effective for cadmium.

It is therefore not a routine cadmium-specific therapy.

Gastric Lavage

Older sources suggested gastric lavage soon after severe ingestion.

Routine gastric lavage is not part of contemporary standard poisoning management and would only be considered under exceptional circumstances with:

• A potentially life-threatening recent ingestion
• Protected airway
• Medical-toxicology consultation

Skin and Eye Exposure

For contaminated skin:

• Remove contaminated clothing
• Wash thoroughly with soap and water

For eye exposure:

• Irrigate copiously with water or saline

Persistent ocular irritation warrants examination.

Antidote

There is no established specific antidote for cadmium poisoning.

Chelation

Routine Chelation Is Not Recommended

This is an important update from the older source.

Although chelators may increase urinary cadmium excretion, they can also redistribute cadmium and increase renal cadmium delivery.

ATSDR states that chelation has no established role in routine cadmium poisoning management.

Dimercaprol (BAL)

Dimercaprol should not be used for cadmium poisoning.

It can form cadmium complexes that increase renal toxicity. ATSDR specifically identifies BAL as potentially harmful in cadmium exposure.

CaNa₂EDTA

Older references suggested CaNa₂EDTA after acute exposure.

This is now highly controversial because EDTA may:

• Increase urinary cadmium
• Mobilize cadmium toward the kidney
• Increase renal cortical cadmium concentrations
• Worsen nephrotoxicity

Therefore:

Do not routinely administer EDTA for cadmium poisoning.

Any consideration of chelation in an exceptional acute case should involve an experienced medical toxicologist.

Chronic Cadmium Toxicity

There is no established role for chelation in chronic cadmium accumulation.

Primary treatment is:

Stop further exposure

before irreversible renal injury progresses.

Hemodialysis

Hemodialysis does not effectively remove the established cadmium body burden, largely because cadmium becomes strongly bound to proteins and tissues.

Therefore:

Dialysis is not an enhanced-elimination treatment for cadmium itself.

However, dialysis should be used when conventional indications from acute kidney injury develop, such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Fluid overload
• Uremic complications

Hypotension

Treat shock with:

• Appropriate isotonic crystalloid
• Blood products when clinically indicated
• Vasopressors if hypotension persists

Modern management does not preferentially require dopamine; vasopressor choice should follow contemporary shock physiology, with norepinephrine commonly preferred for persistent distributive hypotension.

Chronic Kidney Disease

Management includes:

• Complete removal from further cadmium exposure
• Avoidance of nephrotoxins
• Blood-pressure management
• Monitoring GFR and proteinuria
• Nephrology follow-up

Renal dysfunction may continue to progress even after exposure has stopped because of the extraordinarily long tissue half-life and irreversible tubular injury.

Bone Disease

For osteomalacia/osteoporosis:

• Correct calcium abnormalities
• Correct vitamin D deficiency
• Correct phosphate abnormalities
• Manage chronic kidney disease
• Treat osteoporosis according to standard clinical criteria

Simply administering calcium and vitamin D does not reverse the underlying cadmium body burden.

Occupational Exposure Standards

The older occupational limits are substantially outdated.

OSHA PEL

Current OSHA permissible exposure limit:

5 μg/m³ (0.005 mg/m³) as an 8-hour TWA

for cadmium compounds, dust, and fumes.

OSHA Action Level

2.5 μg/m³ as an 8-hour TWA

Exposure at or above this level can trigger additional occupational monitoring requirements.

NIOSH

NIOSH designates cadmium as an:

Occupational carcinogen (Ca)

and recommends reducing exposure to the lowest feasible concentration rather than giving a conventional numerical REL.

NIOSH IDLH

Current IDLH:

9 mg/m³ as cadmium

—not “9 mg/m².”

This corrects the unit error in the older source.

Smoking

Tobacco is an important source of cadmium exposure.

Therefore, patients with:

• Occupational cadmium exposure
• Elevated cadmium biomarkers
• Cadmium nephrotoxicity

should be strongly encouraged to avoid tobacco exposure.

Smoking can materially increase cadmium body burden.

Pregnancy

Cadmium can cross the placenta, although placental transfer is partly limited by binding within placental tissue.

Environmental and occupational exposure has been associated in epidemiologic research with adverse reproductive and fetal-growth outcomes.

Management should prioritize:

• Termination of exposure
• Occupational/environmental assessment
• Maternal renal and respiratory evaluation
• Obstetric follow-up when exposure is significant

Monitoring

Significant Acute Inhalation

Monitor:

• Respiratory rate
• Oxygen saturation
• Work of breathing
• Serial lung examination
• Chest imaging as indicated
• Blood gas if respiratory distress develops
• Renal function
• Liver enzymes after substantial exposure

Because symptoms may be delayed 4–10 hours or longer, observation duration should be guided by exposure severity rather than a rigid 4–6-hour rule.

Acute Ingestion

Monitor:

• Fluid status
• Electrolytes
• BUN/creatinine
• Urine output
• Liver function
• CBC if GI hemorrhage is suspected

Chronic Exposure

Follow:

• CdU
• CdB
• Urinary β₂-microglobulin or other tubular markers
• Creatinine/eGFR
• Urinalysis/proteinuria
• Blood pressure
• Pulmonary function when occupational inhalation is significant

Admission

Hospital admission is appropriate for:

• Significant cadmium fume inhalation
• Dyspnea
• Hypoxemia
• Pulmonary infiltrates
• Chemical pneumonitis
• Persistent severe vomiting/diarrhea
• Hemorrhagic gastroenteritis
• Significant dehydration
• Acute kidney injury
• Hepatic injury
• Hemodynamic instability

Severe respiratory toxicity warrants ICU-level care.

Prognosis

Acute Oral Exposure

Most patients who survive the initial severe GI illness recover, although significant renal or hepatic injury may require prolonged recovery.

Acute Inhalation

The prognosis depends strongly on the magnitude of exposure.

Severe chemical pneumonitis may lead to:

• ARDS
• Prolonged ventilation
• Pulmonary fibrosis
• Permanent impairment
• Death

Persistent lung dysfunction has been documented years after severe single exposures.

Chronic Exposure

Chronic cadmium-associated renal tubular damage may be irreversible.

Even after exposure stops:

Renal dysfunction may continue to progress.

Important Pitfalls

1. Mistaking cadmium fume poisoning for benign metal fume fever

Both may initially cause:

• Fever
• Chills
• Myalgia
• Cough

But cadmium can progress to:

Chemical pneumonitis + pulmonary edema + respiratory failure

2. Discharging too early after significant inhalation

Respiratory symptoms are characteristically delayed 4–10 hours.

3. Using outdated occupational limits

The old dust/fume values of 0.1–0.2 mg/m³ are far above the current general OSHA PEL.

Current OSHA PEL:

0.005 mg/m³ = 5 μg/m³

4. Misreading the IDLH unit

NIOSH IDLH is:

9 mg/m³

not 9 mg/m².

5. Treating a cadmium level as the diagnosis

Blood cadmium mainly reflects recent exposure.

Urinary cadmium more closely reflects body burden, unless tubular injury has already altered excretion.

Neither provides a perfect stand-alone measure of clinical toxicity.

6. Missing proximal tubular injury

The earliest chronic renal manifestations may be:

• β₂-microglobulinuria
• Retinol-binding proteinuria

before major creatinine elevation.

7. Giving chelation reflexively

Routine EDTA or BAL therapy is not recommended.

BAL may worsen renal toxicity, and EDTA may redistribute cadmium to the kidney.

8. Using dialysis to remove cadmium

Hemodialysis is used for complications of renal failure, not as effective cadmium decontamination.

9. Forgetting tobacco exposure

Smoking adds substantially to lifetime cadmium burden.

High-Yield Toxicology Pearls

Cadmium = lungs acutely, kidneys chronically

Think:

Welding/cutting cadmium metal → delayed fever + cough + dyspnea → chemical pneumonitis

and

Chronic exposure → proximal tubular proteinuria + osteomalacia

Key points:

• Cadmium is a cumulative heavy metal toxin
• Major occupational routes: welding, smelting, batteries, electroplating
• Tobacco is an important nonoccupational source
• Acute inhalation is the most dangerous occupational presentation
• Symptoms may be delayed 4–10 hours
• Severe inhalation can cause noncardiogenic pulmonary edema/ARDS
• Acute ingestion causes severe gastroenteritis
• Chronic target organ: kidney
• Classic chronic lesion: proximal tubular dysfunction
• Early marker: urinary β₂-microglobulin
• Bone complications: osteomalacia, osteoporosis, Itai-itai disease
• Cadmium is IARC Group 1 carcinogenic
• Blood Cd → more reflective of recent exposure
• Urine Cd → more reflective of cumulative body burden
• No specific antidote
• Main therapy: remove exposure + supportive care
• Routine chelation is not recommended
• BAL can worsen cadmium toxicity
• EDTA is controversial and potentially nephrotoxic in cadmium exposure
• Hemodialysis does not meaningfully remove tissue-bound cadmium
• Current OSHA PEL: 5 μg/m³ over 8 hours
• OSHA action level: 2.5 μg/m³
• NIOSH IDLH: 9 mg/m³
• Prevention and occupational exposure control are central because established chronic renal injury may be irreversible

Toxicology – Butorphanol

Core concept

Butorphanol is a synthetic opioid analgesic with mixed opioid-receptor activity.

The major overdose syndrome is the usual opioid toxidrome:

CNS depression + respiratory depression ± miosis

Severe poisoning may progress to:

Hypoventilation → hypoxia → coma → respiratory arrest

The most important treatment priorities are:

Airway/ventilation + naloxone when clinically significant opioid respiratory depression is present

Current product labeling specifically identifies respiratory depression as the major life-threatening manifestation of overdose.

Forms and Uses

Butorphanol remains available in human formulations including:

• Nasal spray
• IV/IM injection

Current nasal spray contains 10 mg/mL, with each metered spray delivering approximately 1 mg.

Current injectable preparations include concentrations such as:

• 1 mg/mL
• 2 mg/mL

For analgesia, current labeling lists a usual adult dose of:

• 1 mg IV
• 2 mg IM

with dose individualization according to clinical response.

Butorphanol is a Schedule IV controlled substance in the United States.

Pathophysiology

The older description of butorphanol as simply a μ-antagonist/κ-agonist is incomplete.

Current FDA labeling describes butorphanol as:

• Partial agonist at the μ-opioid receptor
• Full agonist at the κ-opioid receptor

Therefore:

μ/κ opioid-receptor activity → analgesia + sedation + respiratory depression

κ-receptor activity also contributes to:

• Dysphoria
• Psychotomimetic effects
• Unpleasant perceptual symptoms

Butorphanol can produce substantial respiratory depression through direct suppression of brainstem respiratory centers.

Mixed Agonist-Antagonist Effect

Although butorphanol has partial μ-agonist activity, it can functionally oppose the effects of a full μ-opioid agonist.

Therefore, in a patient physically dependent on drugs such as:

• Morphine
• Heroin
• Oxycodone
• Fentanyl
• Methadone

butorphanol may:

Displace/reduce full μ-agonist activity → precipitate acute opioid withdrawal

Current labeling specifically warns that butorphanol may reduce the analgesic effect of full opioid agonists and precipitate withdrawal symptoms.

Toxic Dose

There is no well-defined single toxic dose.

Severity depends on:

• Amount
• Route
• Opioid tolerance
• Age
• Coingestants
• Renal function
• Hepatic function

Therapeutic doses can cause:

• Dizziness
• Sedation
• Dysphoria
• Nausea

Large doses may cause profound opioid toxicity.

Importantly, current labeling warns that accidental exposure to even one dose of nasal butorphanol can cause a fatal overdose in a child.

Thus, tolerance in a chronic user should never be interpreted as protection against serious toxicity.

Pharmacokinetics

Butorphanol is metabolized primarily to hydroxybutorphanol.

Most elimination occurs through the urine.

The usual elimination half-life is approximately several hours, but clearance is significantly prolonged in:

• Renal impairment
• Hepatic impairment
• Older adults

In severe renal impairment, the half-life may approximately double to around 10.5 hours.

In hepatic impairment, the half-life may approximately triple to around 16.8 hours.

Therefore:

Renal/hepatic dysfunction → prolonged toxicity and increased risk of recurrent sedation or respiratory depression

Risk Factors for Severe Toxicity

Greater concern is warranted in:

• Children
• Older adults
• Opioid-naïve patients
• Renal impairment
• Hepatic impairment
• Underlying pulmonary disease
• Sleep-disordered breathing
• Concurrent CNS depressants

Particularly dangerous coexposures include:

• Benzodiazepines
• Alcohol
• Other opioids
• Sedative-hypnotics
• Muscle relaxants
• Antipsychotics
• General anesthetics

The combination of butorphanol with benzodiazepines or other CNS depressants can produce:

Profound sedation + respiratory depression + coma + death.

Clinical Features

Classic Opioid Toxidrome

Think:

Depressed consciousness + hypoventilation + small pupils

However, the full triad is not always present.

Neurologic

Possible manifestations include:

• Drowsiness
• Dizziness
• Sedation
• Dysphoria
• Confusion
• Somnolence
• Stupor
• Coma

Severe overdose may produce:

• Skeletal muscle flaccidity
• Loss of airway reflexes

Current labeling also notes that toxic leukoencephalopathy has been reported after opioid overdose, sometimes presenting after apparent initial recovery.

Pupils

Miosis is typical.

However:

Mydriasis may occur in severe hypoxia

so normal or dilated pupils do not exclude opioid poisoning.

Respiratory

The most important manifestation is:

Respiratory depression

Possible findings include:

• Bradypnea
• Shallow breathing
• Reduced tidal volume
• Hypoventilation
• Hypercapnia
• Hypoxemia
• Upper-airway obstruction
• Snoring respirations
• Apnea

Respiratory arrest is the principal mechanism by which opioid overdose progresses to cardiac arrest.

Cardiovascular

Possible effects include:

• Bradycardia
• Hypotension
• Peripheral vasodilation

Rarely:

• Hypertension
• Dysrhythmia secondary to severe hypoxia or other factors

Severe circulatory depression may require vasopressor support.

Pulmonary Edema

Noncardiogenic pulmonary edema may occur after severe opioid overdose.

Possible findings:

• Dyspnea
• Hypoxemia
• Crackles
• Frothy secretions
• Bilateral infiltrates

Treatment is supportive, including positive-pressure ventilation when needed.

Gastrointestinal

Possible manifestations include:

• Nausea
• Vomiting
• Reduced gastrointestinal motility
• Constipation

Nausea and vomiting can occur even at therapeutic doses.

Metabolic

Hypoglycemia has been reported with opioids, including current butorphanol labeling.

Therefore:

Check glucose in any patient with altered mental status.

Diagnosis

Diagnosis is primarily clinical:

Known/suspected butorphanol exposure + opioid toxidrome

Do not delay treatment while waiting for toxicology testing.

Essential Assessment

Evaluate:

• Airway
• Respiratory rate
• Depth of ventilation
• Oxygen saturation
• Mental status
• Pupils
• Heart rate
• Blood pressure
• Bedside glucose

Ventilation Assessment

Pulse oximetry alone may be misleading, particularly if supplemental oxygen has been given.

A patient can have:

• Normal SpO₂
• Severe hypoventilation
• Rising CO₂

Therefore, consider:

• Continuous capnography
• Blood gas

when significant respiratory depression is present.

Additional Tests

Depending on severity:

• ECG
• Electrolytes
• BUN/creatinine
• Liver tests
• Blood gas
• Chest radiograph if aspiration or pulmonary edema is suspected

In intentional overdose consider:

• Acetaminophen concentration
• Salicylate concentration
• Evaluation for coingestants

Urine Drug Screening

A routine “opiate” urine immunoassay primarily detects morphine-like compounds.

Many structurally different synthetic and semisynthetic opioids are not reliably detected by standard screening assays. ACMT emphasizes that management of acute opioid poisoning should be based on the clinical presentation rather than a screening test result.

Older literature specifically notes that butorphanol may not be detected by common opioid immunoassays.

Therefore:

A negative routine urine opioid screen does not exclude butorphanol poisoning.

Differential Diagnosis

Other causes of:

CNS depression + respiratory depression ± miosis

include:

• Fentanyl
• Heroin
• Morphine
• Methadone
• Oxycodone
• Buprenorphine
• Clonidine
• Other sedative-hypnotics

Also consider:

• Benzodiazepine poisoning
• Alcohol intoxication
• Hypoglycemia
• Hypercapnia
• Intracranial hemorrhage
• Stroke
• CNS infection

Treatment

1. Airway and Breathing Come First

The most important principle is:

Ventilate the patient.

AHA guidance for life-threatening opioid poisoning emphasizes:

• Opening the airway
• Rescue breathing or bag-mask ventilation
• Supplemental oxygen as appropriate

before or while opioid antagonist therapy is being given.

If ventilation remains inadequate:

• Bag-mask ventilate
• Consider supraglottic airway
• Intubate if necessary

Do not wait for naloxone to work if the patient is severely hypoventilating.

Naloxone

Role

Naloxone is the specific antidotal treatment for clinically significant butorphanol-induced respiratory or circulatory depression.

Current naloxone labeling specifically includes butorphanol among opioids whose respiratory depression may be reversed by naloxone.

Treatment Goal

The goal is:

Adequate spontaneous ventilation and airway protection

not necessarily complete awakening.

A somnolent patient who is:

• Breathing adequately
• Maintaining the airway
• Hemodynamically stable

may not require aggressive naloxone dosing. AHA notes that patients with opioid exposure who are breathing normally with intact airway reflexes may be carefully observed.

Adult Naloxone Dose

FDA-labeled treatment for known or suspected opioid overdose is:

0.4–2 mg IV

repeated every:

2–3 minutes

if adequate respiratory improvement does not occur.

If there is no response after a cumulative 10 mg, another diagnosis or substantial non-opioid contribution should be considered.

Opioid-Dependent Patients

In a patient with known or suspected opioid dependence, rapid complete reversal can precipitate severe withdrawal.

A cautious approach is to use small IV doses, for example:

0.04–0.4 mg IV, titrated every few minutes to adequate ventilation.

The principle is:

Titrate to breathing, not wakefulness.

Butorphanol May Require More Naloxone

An important butorphanol-specific point:

Larger naloxone doses may sometimes be required because butorphanol is a mixed opioid agonist/antagonist with strong receptor affinity.

Current butorphanol labeling explicitly warns of this possibility.

Recurrent Toxicity

Naloxone may wear off before butorphanol.

Therefore:

Response to naloxone does not mean the patient is safe for immediate discharge.

Patients must be monitored for:

• Recurrent sedation
• Recurrent respiratory depression
• Need for repeat naloxone

Current labeling specifically states that patients should be monitored until spontaneous respiration is reliably re-established because opioid reversal may be shorter than butorphanol’s duration of action.

Naloxone Infusion

If repeated naloxone boluses are required to maintain adequate ventilation, a continuous naloxone infusion may be appropriate.

The infusion is titrated to:

• Respiratory rate
• Ventilation
• Mental status sufficient for airway protection

rather than to complete alertness.

Precipitated Withdrawal

Naloxone may precipitate:

• Agitation
• Vomiting
• Diaphoresis
• Tachycardia
• Hypertension
• Severe pain
• Acute withdrawal

Butorphanol itself may also precipitate withdrawal in patients dependent on full μ-opioid agonists.

This is why both:

• Naloxone
• Butorphanol exposure

require particular care in opioid-dependent patients.

Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not induce emesis.

Opioid poisoning can rapidly produce:

• Sedation
• Loss of airway reflexes
• Aspiration

The historical recommendation for emesis should not be used.

Activated Charcoal

Routine activated charcoal is not necessary for most butorphanol exposures.

It might be considered after a substantial, very recent oral ingestion if:

• The airway is fully protected
• Aspiration risk is low
• A clinically meaningful oral dose was actually swallowed

However, airway stabilization and ventilation take priority.

Gastric Lavage

Routine gastric lavage is not recommended.

Hypotension

Treat clinically significant hypotension with:

• IV crystalloid when appropriate
• Vasopressors if shock persists

Current labeling specifically supports vasopressors when required for circulatory shock.

Pulmonary Edema

Management includes:

• Oxygen
• Positive-pressure ventilation when necessary
• Appropriate ventilatory support

Treatment should focus on oxygenation and ventilation rather than routine diuresis unless another indication exists.

Cardiac Arrest

For opioid-associated cardiac arrest:

High-quality CPR and ventilation take priority.

Naloxone may be given if opioid poisoning is suspected, but it should not delay standard resuscitation.

Enhanced Elimination

There is no established role for:

• Hemodialysis
• Hemoperfusion
• Urinary alkalinization

in routine butorphanol overdose.

Management is primarily:

• Ventilatory support
• Naloxone
• Supportive care

Monitoring

Symptomatic patients require:

• Continuous pulse oximetry
• Respiratory-rate monitoring
• Frequent mental-status assessment
• Cardiac monitoring in significant poisoning

Consider:

• Continuous capnography

for significant respiratory depression.

Also monitor:

• Glucose
• Blood pressure
• Renal function when prolonged toxicity is possible

Observation and Disposition

The historical fixed 4-hour observation period should not be applied automatically to every patient.

Observation should be individualized according to:

• Dose
• Route
• Clinical severity
• Naloxone requirement
• Coingestants
• Renal function
• Hepatic function

Patients who require naloxone should be observed until:

• Respiratory function is reliably normal
• Mental status is stable
• Vital signs are stable
• Risk of recurrent opioid toxicity is sufficiently low

AHA specifically recommends continued healthcare observation after naloxone when recurrent toxicity remains possible.

Admission

Hospital admission is appropriate for:

• Persistent respiratory depression
• Repeated naloxone requirements
• Naloxone infusion
• Coma
• Aspiration
• Pulmonary edema
• Hemodynamic instability
• Significant coingestants
• Prolonged toxicity from renal/hepatic dysfunction

Severe toxicity requiring ventilatory support warrants ICU care.

Pregnancy

The historical FDA pregnancy categories such as Category C are obsolete.

Current FDA labeling instead provides narrative pregnancy-risk information.

Important points include:

• Butorphanol crosses the placenta
• Prolonged maternal opioid use can cause neonatal opioid withdrawal syndrome
• Maternal overdose should still be treated promptly, with maternal airway and ventilation as the priority

Current labeling warns that prolonged use during pregnancy may cause potentially serious neonatal withdrawal.

Breastfeeding

Butorphanol can pass into breast milk.

Current labeling advises monitoring exposed infants for:

• Excessive sleepiness
• Respiratory difficulty
• Limpness

because these may indicate opioid toxicity.

Prognosis

With prompt recognition and adequate ventilation:

Complete recovery is expected in most isolated butorphanol overdoses.

Poor outcomes usually result from:

• Delayed recognition
• Prolonged hypoxia
• Aspiration
• Severe coingestion
• Respiratory arrest

Potential post-hypoxic neurologic injury depends more on the duration of hypoxia than on a direct neurotoxic effect of butorphanol.

Important Pitfalls

1. Treating the patient’s level of consciousness instead of ventilation

Naloxone should be titrated primarily to:

Adequate ventilation and airway protection

rather than complete wakefulness.

2. Waiting for naloxone instead of ventilating

A severely hypoventilating patient needs immediate:

• Airway opening
• Bag-mask ventilation

Naloxone is an adjunct to, not a replacement for, respiratory support.

3. Using a negative urine opioid screen to exclude poisoning

Routine opioid immunoassays may not detect butorphanol.

Clinical findings are more important than the screen.

4. Forgetting precipitated withdrawal

Butorphanol may provoke withdrawal in a patient dependent on a full μ-opioid agonist.

Naloxone can do the same.

5. Assuming respiratory depression has a complete ceiling

Butorphanol may show some ceiling characteristics at higher therapeutic doses, but life-threatening and fatal respiratory depression remains possible, particularly with overdose or CNS depressant coingestion.

6. Missing recurrent toxicity after naloxone

Naloxone may wear off before butorphanol.

Continue respiratory observation after an initial response.

7. Missing renal or hepatic impairment

Butorphanol elimination may be substantially prolonged in:

• Severe renal disease
• Hepatic impairment

so monitoring may need to be extended.

8. Combining butorphanol with benzodiazepines or alcohol

The combination markedly increases risk of:

• Profound sedation
• Respiratory depression
• Coma
• Death

High-Yield Toxicology Pearls

Butorphanol overdose = opioid toxidrome

Think:

Somnolence/coma + respiratory depression ± miosis

Key points:

• Butorphanol is a synthetic Schedule IV opioid
• Current receptor description:
• Partial μ agonist
• Full κ agonist
• κ activity may cause dysphoria/psychotomimetic effects
• Main life-threatening toxicity: respiratory depression
• Severe overdose may cause:
• Coma
• Bradycardia
• Hypotension
• Pulmonary edema
• Respiratory arrest
• A single accidental nasal dose can be dangerous to a small child
• Coingestion with benzodiazepines, alcohol, or other CNS depressants markedly increases toxicity
• Butorphanol may precipitate opioid withdrawal in patients dependent on full μ agonists
• Main treatment: airway + ventilation
• Antidote: naloxone
• FDA naloxone overdose dosing: 0.4–2 mg IV, repeat every 2–3 min as needed
• In opioid-dependent patients, use smaller titrated naloxone doses
• Goal of naloxone: restore adequate breathing, not necessarily complete alertness
• Butorphanol may require larger cumulative naloxone doses
• Monitor for recurrent respiratory depression
• A negative routine urine opioid screen does not exclude butorphanol
• Routine activated charcoal and gastric lavage are not required
• Renal and hepatic impairment can substantially prolong elimination
• Most patients recover completely if hypoxia is prevented

Toxicology – Brown Recluse Spider Bite

Core concept

Brown recluse (Loxosceles reclusa) envenomation causes a cytotoxic/hemolytic syndrome called loxoscelism.

Two major clinical patterns occur:

Cutaneous loxoscelism → local inflammation ± delayed dermonecrosis

Systemic loxoscelism → fever + intravascular hemolysis ± DIC, rhabdomyolysis, acute kidney injury, shock

The most important severe systemic complication is:

Acute hemolytic anemia

particularly in children.

Geographic Distribution

The true brown recluse, Loxosceles reclusa, is established mainly in the south-central and Midwestern United States.

It is widely overdiagnosed outside its endemic range. Other Loxosceles species occur in other parts of the United States and worldwide.

This matters because:

A necrotic skin lesion is not automatically a brown recluse bite.

Many presumed bites are actually:

• Bacterial skin infections
• Inflammatory skin disease
• Vascular lesions
• Other dermatologic disorders

Identification

Brown recluse spiders are generally:

• Tan to brown
• Uniformly colored
• Long-legged
• Relatively small

Characteristic features include:

• Six eyes arranged in three pairs
• Dark violin-like marking on the cephalothorax

However, the violin marking is not sufficiently specific by itself to identify the spider reliably.

The strongest confirmation occurs when:

The spider is actually observed biting the patient and subsequently identified by an expert.

Toxic Dose

A single envenomating bite can cause toxicity.

However, most bites do not result in severe dermonecrosis or systemic illness.

Severity depends on:

• Quantity of venom delivered
• Bite location
• Patient age
• Individual inflammatory response

Children have a greater risk of clinically significant systemic loxoscelism.

Pathophysiology

Brown recluse venom contains several biologically active enzymes.

The most important is:

Sphingomyelinase D

This contributes to:

• Endothelial injury
• Complement activation
• Leukocyte recruitment
• Local inflammation
• Microvascular injury
• Tissue necrosis
• Red-cell destruction

Therefore:

Sphingomyelinase D → inflammation + vascular injury → dermonecrosis

and

Sphingomyelinase D/complement activation → erythrocyte injury → hemolysis

Other venom enzymes act synergistically and contribute to tissue destruction.

Clinical Features

Initial Bite

The bite is frequently:

Initially painless or only mildly painful

The patient may therefore never notice the spider.

Within approximately 2–8 hours, the site may become:

• Painful
• Pruritic
• Erythematous
• Swollen

Evolution of the Local Lesion

A more significant bite may progress through:

Erythema → central pallor → blister → blue/violet discoloration → eschar/necrosis

A characteristic lesion may contain three zones:

• Central dusky or violaceous area
• Pale ischemic zone
• Outer erythematous region

This is sometimes described as a:

“Red, white, and blue” lesion

However, this appearance is not present in every case and is not independently diagnostic.

Important Timing

One of the most useful diagnostic principles is:

Brown recluse wounds do not usually ulcerate immediately.

True ulceration generally develops later, often approximately:

7–14 days after the bite

A lesion that is already ulcerated or frankly necrotic within the first few hours is therefore less typical of brown recluse envenomation.

Dermonecrosis

More severe lesions may progress to:

• Hemorrhagic blister
• Central eschar
• Full-thickness ulcer
• Subcutaneous tissue loss

The wound may take:

Weeks to months

to heal.

Most bites, however, do not progress to extensive necrosis.

Systemic Loxoscelism

Systemic illness is uncommon but potentially life-threatening.

Possible manifestations include:

• Fever
• Chills
• Malaise
• Headache
• Myalgia
• Arthralgia
• Nausea
• Vomiting

Severe manifestations include:

• Hemolytic anemia
• Hemoglobinuria
• Rhabdomyolysis
• Acute kidney injury
• DIC
• Hypotension
• Seizures
• Multiorgan failure

Children are disproportionately represented among severe systemic cases.

Hemolysis

Major systemic complication

The most important systemic complication is:

Acute intravascular hemolysis

Patients may develop:

• Rapidly falling hemoglobin
• Jaundice
• Dark urine
• Weakness
• Tachycardia
• Pallor
• Elevated LDH
• Low haptoglobin
• Reticulocytosis
• Indirect hyperbilirubinemia

Hemolysis can be:

• Direct
• Complement mediated
• Occasionally associated with a positive direct antiglobulin test

Delayed hemolysis

A particularly important point:

Hemolysis may not occur immediately.

It has been reported several days after the bite and may develop as late as approximately 7 days afterward.

In one pediatric series, hemolysis demonstrated both earlier and later presentations, with some occurring roughly a week after the bite.

Therefore, an initially normal CBC does not always exclude subsequent systemic loxoscelism.

Renal Toxicity

Acute kidney injury may develop secondary to:

• Hemoglobinuria
• Rhabdomyolysis
• Hypotension
• Severe systemic inflammation

Possible findings:

• Rising creatinine
• Oliguria
• Hematuria/hemoglobinuria
• Hyperkalemia

Rare severe cases require renal replacement therapy.

Coagulation

Severe systemic loxoscelism may occasionally cause:

• Thrombocytopenia
• Coagulation abnormalities
• Disseminated intravascular coagulation

This is uncommon and suggests severe systemic disease.

Neurologic

Severe systemic illness may cause:

• Lethargy
• Altered consciousness
• Seizures
• Coma

These findings should prompt evaluation for severe hemolysis, shock, metabolic abnormalities, and alternative diagnoses.

Diagnosis

There is no routinely available definitive laboratory test for brown recluse envenomation.

The diagnosis is usually clinical.

Definitive attribution is strongest when:

• The bite was witnessed
• The spider was captured
• The spider was expertly identified

Otherwise, the diagnosis should remain cautious.

NOT RECLUSE

A useful mnemonic helps identify lesions that are less likely to represent a brown recluse bite:

N — Numerous

Brown recluse bites usually produce one lesion, not many.

O — Occurrence

The exposure should make sense—for example, disturbing clothing, boxes, bedding, attics, or other secluded spaces.

T — Timing

In endemic U.S. regions, bites occur predominantly during warmer months.

R — Red center

The center is often pale or violaceous, rather than simply bright red.

E — Elevated

The lesion is generally fairly flat rather than markedly raised.

C — Chronic

Most lesions should substantially heal within approximately 3 months.

L — Large

Lesions are rarely larger than approximately 10 cm.

U — Ulcerates too early

Ulceration before about 7 days argues against classic recluse envenomation.

S — Swollen

Marked generalized swelling is unusual except in certain locations such as the face or feet.

E — Exudative

Purulent or heavily exudative lesions suggest another diagnosis, especially bacterial infection.

Differential Diagnosis

This is one of the most important aspects of brown recluse toxicology.

Many conditions are incorrectly diagnosed as spider bites.

Consider:

• Staphylococcus aureus / MRSA infection
• Cellulitis
• Abscess
• Necrotizing soft-tissue infection
• Pyoderma gangrenosum
• Vasculitis
• Diabetic ulcer
• Arterial or venous ulcer
• Pressure injury
• Herpes zoster
• Cutaneous anthrax
• Deep fungal infection
• Ecthyma
• Other arthropod bites

Purulence, multiple lesions, rapid ulceration, or occurrence far outside an endemic region should especially prompt reconsideration of the diagnosis.

Laboratory Evaluation

Mild Local Disease

Patients with only a mild local lesion generally do not require extensive laboratory testing.

Systemic Symptoms

If there is:

• Fever
• Malaise
• Dark urine
• Jaundice
• Weakness
• Significant vomiting
• Myalgia
• Altered mental status

particularly in a child, consider:

Hematologic

• CBC
• Hemoglobin/hematocrit
• Reticulocyte count
• Peripheral smear
• LDH
• Haptoglobin
• Bilirubin

Renal/metabolic

• Electrolytes
• BUN
• Creatinine
• Urinalysis

Muscle injury

• CK

Coagulation

If systemic illness is severe:

• PT/INR
• aPTT
• Fibrinogen
• D-dimer
• Platelet count

Urinalysis

Urinalysis can be particularly useful for detecting:

• Hemoglobinuria
• Myoglobinuria
• Renal involvement

In children with a convincing suspected bite who are being discharged, at least an initial urinalysis has been recommended because hemolysis may be delayed.

Treatment

1. Local First Aid

Initial treatment includes:

• Clean the wound with soap and water
• Elevate the affected extremity when appropriate
• Apply intermittent cold packs
• Provide analgesia
• Update tetanus immunization if indicated

Local cooling is reasonable because sphingomyelinase-D activity is temperature dependent and may decrease with cooling.

Avoid heat application.

2. Analgesia

For mild-to-moderate pain:

• Acetaminophen
• NSAIDs when appropriate

More severe pain may require:

• Short-term opioid analgesia

3. Antibiotics

Prophylactic antibiotics are not recommended.

Brown recluse venom injury is not a bacterial infection.

Antibiotics should be given only when there is evidence of:

• Cellulitis
• Abscess
• Secondary bacterial infection

This is particularly important because bacterial abscesses are frequently mistaken for spider bites.

4. Wound Care

Use:

• Gentle cleansing
• Appropriate dressings
• Monitoring for progression
• Analgesia

Large wounds may eventually require:

• Wound-care consultation
• Surgical evaluation
• Delayed grafting

Surgery

Avoid Early Excision

Early surgical excision or debridement is not recommended.

The eventual zone of necrosis is difficult to determine during the first days.

Premature excision can:

• Remove viable tissue
• Enlarge the defect
• Increase scarring
• Delay healing

Current reviews recommend allowing the lesion to become well demarcated before considering surgical treatment.

Delayed Surgery

When a large necrotic defect persists after demarcation, options may include:

• Debridement
• Delayed excision
• Skin grafting

This may not be necessary until several weeks after injury.

Dapsone

Older literature frequently recommended dapsone to inhibit neutrophil-mediated injury.

Modern practice does not routinely recommend dapsone because:

• Clinical evidence of benefit is weak
• It can cause hemolytic anemia
• It can cause methemoglobinemia
• Risk is particularly high in G6PD deficiency
• Serious hypersensitivity reactions can occur

This is especially problematic because brown recluse envenomation itself can cause hemolysis.

Therefore:

Dapsone is generally avoided.

Corticosteroids

Local Cutaneous Disease

Routine systemic corticosteroids have not been proven to prevent dermonecrosis and are not standard therapy for uncomplicated cutaneous loxoscelism.

Severe Hemolysis

Some systemic cases develop immune-mediated/warm autoimmune hemolytic anemia.

In those selected patients, corticosteroids may be used in consultation with:

• Hematology
• Medical toxicology

A 2022 clinical series describes corticosteroid treatment for confirmed warm autoimmune hemolytic anemia secondary to systemic loxoscelism.

Therefore:

Steroids are not routine bite therapy; they may have a role in a specific hematologic complication.

Hyperbaric Oxygen

Hyperbaric oxygen has historically been proposed to reduce dermonecrosis.

Evidence remains insufficient for routine use.

It is not standard first-line therapy for uncomplicated brown recluse bites.

Antivenom

There is no routinely available specific brown recluse antivenom in the United States.

Antivenoms for other Loxosceles species are used in some other countries, but this does not alter routine U.S. management of L. reclusa bites.

Treatment of Systemic Loxoscelism

Hemolytic Anemia

Management may require:

• IV fluids when appropriate
• Serial hemoglobin
• Renal monitoring
• Packed RBC transfusion for clinically significant anemia

Transfusion is based on:

• Hemodynamic status
• Symptoms
• Rate of hemoglobin decline
• Overall clinical condition

not merely a fixed laboratory threshold.

Acute Kidney Injury

Management includes:

• Maintaining adequate perfusion
• Avoiding nephrotoxins
• Monitoring potassium
• Monitoring urine output
• Treating severe hemolysis/rhabdomyolysis

Severe renal failure may require:

Hemodialysis

Rhabdomyolysis

Monitor:

• CK
• Potassium
• Creatinine
• Urine output

Treat according to standard rhabdomyolysis principles.

DIC

If DIC develops:

• Treat systemic envenomation supportively
• Replace blood components when clinically indicated
• Monitor coagulation closely

Admission

Hospital admission is appropriate for:

• Hemolytic anemia
• Significant fall in hemoglobin
• Hemoglobinuria
• Rhabdomyolysis
• Acute kidney injury
• DIC
• Hypotension
• Significant systemic illness
• Seizures
• Severe vomiting/dehydration

Children with significant systemic symptoms warrant a particularly low threshold for admission.

Severe multiorgan toxicity may require ICU care.

Follow-Up

Because both the skin lesion and systemic toxicity can evolve after presentation, follow-up is important.

Patients should be instructed to return promptly for:

• Fever
• Increasing weakness
• Jaundice
• Dark urine
• Dyspnea
• Syncope
• Worsening pain
• Rapidly expanding lesion

Children

A crucial point:

Hemolysis may occur several days after the bite, including up to approximately 7 days.

Children with convincing exposure therefore deserve particularly careful follow-up for delayed systemic symptoms.

Prognosis

Most bites result in:

• Mild local symptoms
• No systemic illness
• Complete recovery

More substantial cutaneous lesions may require:

• Weeks to months for healing

Systemic loxoscelism can be severe but is uncommon.

Death is rare, particularly with appropriate recognition and supportive care.

Important Pitfalls

1. Diagnosing every necrotic lesion as a brown recluse bite

This is perhaps the most important pitfall.

Brown recluse bites are frequently overdiagnosed, particularly in places where the spiders are not established.

2. Missing MRSA or another bacterial infection

A purulent abscess or exudative lesion is much more suggestive of bacterial infection than classic loxoscelism.

3. Expecting immediate necrosis

Brown recluse lesions generally evolve over days.

Ulceration during the first hours is atypical.

4. Missing delayed hemolysis

An initially well patient, particularly a child, may later develop:

• Jaundice
• Dark urine
• Weakness
• Rapid anemia

5. Performing early surgical excision

Wait for necrosis to become well demarcated before surgical management.

6. Giving prophylactic antibiotics

Antibiotics do not treat venom-mediated necrosis.

Use them only for documented secondary infection.

7. Using dapsone routinely

Dapsone has uncertain benefit and can itself cause:

• Hemolysis
• Methemoglobinemia
• Severe hypersensitivity

8. Missing renal complications

Severe hemolysis and rhabdomyolysis can cause acute kidney injury.

9. Assuming systemic disease requires dramatic skin necrosis

Especially in children, severe systemic loxoscelism can occur even when the cutaneous lesion is relatively modest.

High-Yield Toxicology Pearls

Brown recluse = delayed dermonecrosis ± systemic hemolysis

Think:

Initially mild bite → painful pale/violaceous lesion → delayed ulceration

and, in severe systemic disease:

Fever + jaundice + dark urine + falling hemoglobin → SYSTEMIC LOXOSCELISM

Key points:

• Spider: Loxosceles reclusa
• Major venom toxin: sphingomyelinase D
• Main local toxicity: dermonecrosis
• Major systemic toxicity: hemolytic anemia
• Children have greater risk of systemic loxoscelism
• Lesions usually do not ulcerate immediately
• Ulceration commonly occurs around 7–14 days
• Severe hemolysis may be delayed for several days
• Diagnosis is clinical; no routine definitive diagnostic test exists
• Brown recluse bite is frequently overdiagnosed
• Remember NOT RECLUSE
• Main local treatment: cleaning + cold packs + elevation + analgesia
• Update tetanus immunization when indicated
• No prophylactic antibiotics
• Avoid early surgical excision
• Dapsone is not routinely recommended
• Routine corticosteroids do not prevent cutaneous necrosis
• No routinely available U.S. antivenom
• Systemic cases require serial CBC/hemolysis and renal monitoring
• Significant anemia may require RBC transfusion
• Severe AKI may require dialysis
• Most patients recover completely

Toxicology – Bromides

Core concept

Bromide intoxication (“bromism”) is an uncommon toxic syndrome caused by excessive accumulation of bromide ions, usually from chronic medicinal or supplemental exposure.

The characteristic syndrome is:

Neuropsychiatric dysfunction + ataxia/tremor + GI symptoms ± bromoderma

with a highly characteristic laboratory clue:

Pseudohyperchloremia + very low or negative anion gap

Modern reviews continue to identify this combination as one of the most useful clues to otherwise easily missed bromide toxicity.

Important distinction

Not every drug whose name contains “bromide” produces clinically significant bromide poisoning.

Bromism is most relevant to compounds that:

• Deliver substantial amounts of free bromide
• Are metabolized to bromide
• Are taken chronically or excessively

Important modern sources include:

• Potassium bromide
• Sodium bromide
• Bromovalerylurea / bromisoval
• Certain anticonvulsant or sedative preparations
• Some imported or internet-purchased medications and supplements

Bromide-containing drugs and supplements remain documented causes of modern bromism.

Bromide vs Bromine vs Bromate

These are different toxicologic entities.

Bromide

Produces bromism, primarily:

• Neurologic
• Psychiatric
• Dermatologic

Bromine gas

Produces primarily:

• Respiratory irritation
• Chemical pneumonitis
• Skin/eye injury

Bromate

Bromate compounds are strong oxidants and can cause:

• Acute kidney injury
• Hemolysis
• Severe gastrointestinal toxicity
• Sensorineural hearing loss

Therefore:

Bromide poisoning ≠ bromine gas poisoning ≠ bromate poisoning.

Pathophysiology

Bromide behaves similarly to chloride and distributes through extracellular fluid.

With excessive exposure:

Bromide accumulates → substitutes for chloride in body fluids → alters neuronal membrane function → CNS/neuropsychiatric toxicity

Bromide is eliminated mainly through the kidneys.

Its elimination is closely related to chloride handling:

Higher chloride availability → increased renal bromide clearance

This explains why saline administration can accelerate elimination.

The normal bromide elimination half-life is prolonged, reported around 10–12 days, which explains why chronic accumulation can occur.

Risk Factors

Bromism is more likely in:

• Chronic bromide use
• Renal impairment
• Older adults
• Dehydration
• High-dose therapy
• Repeated ingestion of bromide-containing medications
• Use of imported or unrecognized bromide-containing supplements

Renal dysfunction is particularly important because it decreases bromide elimination.

Acute vs Chronic Toxicity

Acute Bromide Poisoning

Acute poisoning is less common.

Large exposures may cause:

• Nausea
• Vomiting
• CNS depression
• Confusion
• Ataxia
• Coma

Severe cases may produce:

• Hypotension
• Respiratory depression

Chronic Bromide Poisoning – Bromism

Chronic toxicity is the classic presentation.

Symptoms usually evolve gradually over:

• Days
• Weeks
• Occasionally much longer

The nonspecific presentation often results in delayed diagnosis.

Clinical Features

Neurologic

Common manifestations include:

• Confusion
• Lethargy
• Weakness
• Dysarthria
• Ataxia
• Tremor
• Nystagmus
• Abnormal reflexes
• Headache

More severe toxicity may cause:

• Delirium
• Hallucinations
• Psychosis
• Severe agitation
• Stupor
• Coma

Modern reports emphasize that bromism can mimic numerous neurologic and psychiatric disorders.

Psychiatric

Possible findings include:

• Irritability
• Personality changes
• Confusion
• Emotional disturbance
• Hallucinations
• Delusions
• Acute psychosis

A new psychiatric syndrome accompanied by an unexpectedly low or negative anion gap should raise suspicion for bromide intoxication.

HEENT

Possible findings include:

• Nystagmus
• Diplopia

Occasional cranial-nerve abnormalities have been described.

Dermatologic – Bromoderma

Chronic bromide toxicity may cause bromoderma.

Typical lesions include:

• Acneiform eruptions
• Papules
• Pustules

Less commonly:

• Plaques
• Ulcers
• Bullae
• Granulomatous lesions

The face and trunk may be affected.

Gastrointestinal

Common symptoms include:

• Anorexia
• Nausea
• Vomiting
• Abdominal discomfort
• Weight loss

GI symptoms may precede obvious neurologic manifestations.

Cardiovascular

Severe acute intoxication may rarely cause:

• Tachycardia
• Hypotension

Major cardiovascular toxicity is not a typical feature of chronic bromism.

Pulmonary

Severe poisoning may rarely cause respiratory compromise.

Respiratory manifestations should also prompt consideration of:

• Coingestants
• Aspiration
• Bromine gas rather than bromide exposure

Characteristic Laboratory Finding

Pseudohyperchloremia

One of the most important clues is an apparently extremely elevated serum chloride concentration.

Bromide interferes with some chloride assays, particularly ion-selective electrode methods.

The analyzer may incorrectly interpret bromide as chloride, resulting in:

Falsely high chloride → falsely low calculated anion gap

Negative Anion Gap

The classic laboratory pattern is:

Very high measured Cl⁻ + normal or near-normal Na⁺ and bicarbonate → low or negative anion gap

For example, modern bromism cases have reported apparent chloride values above 175 mmol/L with profoundly negative calculated anion gaps.

Therefore:

Unexplained hyperchloremia + negative anion gap = think bromide or other halide interference

Important nuance

The patient usually does not truly have extreme hyperchloremia.

The correct term is:

Pseudohyperchloremia

Different laboratory analyzers have different degrees of bromide interference, so apparent chloride results can vary significantly depending on the method used.

Diagnosis

Diagnosis is based on:

Compatible exposure + neurologic/psychiatric syndrome + pseudohyperchloremia/negative anion gap + elevated serum bromide

Essential Investigations

Obtain:

• Serum electrolytes
• Chloride
• Bicarbonate
• Calculated anion gap
• BUN
• Creatinine
• Glucose

Also consider:

• Magnesium
• Calcium
• Liver function tests
• CBC

Serum Bromide Concentration

A serum bromide concentration can confirm the diagnosis.

However:

Clinical severity does not correlate perfectly with a single bromide concentration.

Historical texts commonly cite:

• Approximately 50–100 mg/dL as potentially associated with toxicity
• Higher concentrations with increasingly severe toxicity

But clinically important toxicity has occurred at varying concentrations, and modern management should be guided by both:

• Clinical condition
• Bromide concentration

A modern case reported marked neurologic toxicity with a bromide level >100 mg/dL, which resolved after discontinuation and saline therapy.

Confirming Pseudohyperchloremia

When bromism is suspected, discuss the chloride methodology with the laboratory.

Chloride may be rechecked using a method less susceptible to bromide interference.

Discordant chloride measurements between:

• Ion-selective electrode
• Alternative/colorimetric methods

can support the diagnosis.

Differential Diagnosis

Because bromism is a “great mimicker,” consider:

Toxicologic

• Lithium
• Phenytoin
• Carbamazepine
• Barbiturates
• Benzodiazepines
• Alcohol
• Other sedative-hypnotics

Neurologic

• Stroke
• Intracranial hemorrhage
• Brain tumor
• Cerebellar disease
• Encephalitis
• Meningitis

Metabolic

• Uremia
• Electrolyte abnormalities
• Hepatic encephalopathy

Psychiatric

• Acute psychosis
• Delirium from another cause

The combination of neurologic/psychiatric symptoms with a negative anion gap is especially suggestive of halide intoxication.

Treatment

1. Stop Bromide Exposure

Immediately discontinue:

• Bromide medication
• Bromide-containing supplement
• Suspected imported preparation

A careful medication history is essential.

Specifically ask about:

• OTC medications
• Foreign medications
• Herbal or dietary supplements
• Anticonvulsants
• Sedatives
• Internet-purchased preparations

2. Supportive Care

Treatment begins with:

• Airway assessment
• Respiratory support when required
• IV access
• Fluid assessment
• Correction of electrolyte abnormalities

There is no specific antidote.

Chloride / Saline Therapy

The principal enhanced-elimination strategy is chloride administration, usually with isotonic saline when clinically appropriate.

The principle is:

More chloride delivered to the kidney → increased bromide excretion

Modern literature continues to describe saline administration as a mainstay of treatment.

IV Saline

For dehydrated or symptomatic patients:

0.9% sodium chloride may be administered with careful attention to:

• Volume status
• Cardiac function
• Renal function
• Sodium
• Potassium
• Urine output

Clinical and laboratory improvement may occur rapidly once exposure is stopped and chloride delivery increases.

Avoid Uncontrolled “Forced Diuresis”

Older references recommended very high fluid rates plus routine diuretics.

Although increasing chloride delivery and urinary output enhances bromide clearance:

Aggressive forced diuresis should not be applied indiscriminately.

Potential complications include:

• Fluid overload
• Electrolyte abnormalities
• Worsening heart failure
• Further dehydration if diuretics exceed replacement

Fluid therapy should therefore be individualized.

Diuretics

Loop or thiazide diuretics have historically been used to enhance bromide elimination.

However:

Routine diuretic therapy has not been shown to improve patient-centered outcomes.

It may be considered only in selected circumstances with careful monitoring rather than as mandatory treatment.

Hemodialysis

Bromide is readily dialyzable.

Hemodialysis can dramatically accelerate bromide elimination and clinical recovery.

A published severe case found that hemodialysis shortened the bromide elimination half-life to approximately 1.4 hours and produced rapid neurologic improvement.

When to Consider Hemodialysis

Consider intermittent hemodialysis in severe bromism, particularly with:

• Significant renal impairment
• Severe encephalopathy
• Coma
• Severe neuropsychiatric toxicity
• Failure to improve with discontinuation and saline therapy
• Inability to administer sufficient chloride/fluids safely
• Very high systemic bromide burden with severe symptoms

Modern reviews identify hemodialysis as an important option for severe or refractory cases.

Why Dialysis Is Effective

Bromide:

• Is a small ion
• Has a relatively small volume of distribution
• Is largely extracellular
• Is normally cleared renally

These characteristics make extracorporeal removal effective.

Gastrointestinal Decontamination

Do Not Induce Vomiting

The historical recommendation for ipecac-induced emesis is obsolete.

Do not induce vomiting.

Gastric Lavage

Routine gastric lavage is not recommended in modern poisoning management.

It should not be performed simply because bromide ingestion occurred.

Activated Charcoal

Activated charcoal is not a central therapy for bromide ion poisoning.

Its utility depends partly on the specific formulation and any coingestants rather than on adsorption of bromide itself.

In a significant recent intentional ingestion, toxicology consultation is preferable to routine charcoal administration.

Monitoring

Symptomatic patients should have serial assessment of:

• Mental status
• Neurologic examination
• Electrolytes
• Apparent chloride
• Anion gap
• BUN
• Creatinine
• Fluid balance

When available:

• Serial serum bromide concentrations

The trend in clinical status is more important than achieving an arbitrary bromide concentration.

Admission

Hospital admission is appropriate for:

• Altered mental status
• Significant ataxia
• Psychosis or delirium
• Persistent vomiting/dehydration
• Renal insufficiency
• Severe electrolyte abnormalities
• Hypotension
• Large intentional exposure
• Need for dialysis

Severe encephalopathy or respiratory compromise warrants ICU-level care.

Prognosis

Bromism is usually reversible when recognized and treated.

Acute toxicity may improve over:

• Hours to several days

Chronic toxicity may require:

• Days to weeks for complete neurologic recovery

because bromide normally has a long elimination half-life.

Modern reports demonstrate complete neurologic recovery after bromide withdrawal and enhanced elimination.

Rarely, prolonged severe toxicity has historically been associated with persistent neurologic abnormalities such as:

• Ataxia
• Tremor
• Dysarthria
• Hyperreflexia

Pregnancy and Neonates

Bromide crosses the placenta.

Maternal chronic exposure can potentially produce neonatal bromide accumulation and CNS depression.

Significant exposure during pregnancy therefore warrants:

• Maternal assessment
• Toxicology consultation
• Appropriate fetal/obstetric monitoring according to severity

Important Pitfalls

1. Missing the negative anion gap

The classic clue is:

Pseudohyperchloremia + negative anion gap

This combination should immediately raise consideration of bromide intoxication.

2. Treating the apparent chloride value as real

A chloride concentration of 170–250 mmol/L in a clinically inconsistent setting may represent analytical interference, not true chloride excess.

3. Failing to ask about supplements or imported medicines

Modern cases continue to occur from:

• OTC medications
• Foreign medications
• Antiepileptic preparations
• Internet-purchased supplements

4. Assuming every “bromide” drug causes bromism

Many medications are formulated as bromide salts but deliver insufficient free bromide under normal use to cause classic bromism.

Exposure history must identify the actual bromide burden.

5. Confusing bromide with bromate

Bromate poisoning causes prominent renal and ototoxic injury and is a different toxicologic syndrome.

6. Confusing bromide with bromine gas

Bromine gas primarily causes:

• Pulmonary irritation
• Chemical pneumonitis
• Eye and skin injury

rather than classic bromism.

7. Overusing forced diuresis

Saline can enhance elimination, but aggressive fluid/diuretic regimens can produce:

• Volume overload
• Electrolyte disturbances

Treatment should be individualized.

8. Delaying dialysis in severe toxicity

Hemodialysis can produce rapid bromide clearance and should be considered early when severe neurologic toxicity or renal impairment is present.

High-Yield Toxicology Pearls

Bromide toxicity = bromism

Think:

Confusion/psychosis + ataxia/tremor + apparent hyperchloremia + negative anion gap

Key points:

• Chronic poisoning is more common than acute poisoning
• Bromism mainly causes neurologic and psychiatric toxicity
• Common findings: confusion, dysarthria, ataxia, tremor, nystagmus
• Dermatologic manifestation: bromoderma
• Bromide is eliminated predominantly by the kidneys
• Renal impairment and dehydration increase toxicity
• Classic laboratory clue: pseudohyperchloremia
• Bromide interferes with some chloride assays
• Result: very low or negative anion gap
• Confirm with a serum bromide concentration
• No specific antidote
• Stop the bromide-containing product
• Saline/chloride administration increases renal bromide elimination
• Routine forced diuresis is not necessary
• Hemodialysis is highly effective in severe or refractory bromism
• Ipecac and routine gastric lavage are obsolete
• Bromism is distinct from both bromine gas and bromate poisoning
• Most patients recover when the diagnosis is recognized and the exposure is stopped

Toxicology – Brodifacoum and Long-Acting Anticoagulants

Core concept

Long-acting anticoagulant rodenticides (LAARs), historically called “superwarfarins,” are potent vitamin K antagonists used as rodenticides.

The characteristic toxicity is:

Delayed vitamin K–dependent coagulopathy → spontaneous bleeding

The most important distinguishing feature is their very prolonged duration of action:

Warfarin → days

Brodifacoum/other LAARs → weeks to months

Therefore, severe poisoning may require high-dose vitamin K₁ for many weeks or months.

Important Agents

Important long-acting anticoagulant rodenticides include:

• Brodifacoum
• Bromadiolone
• Difenacoum
• Difethialone
• Flocoumafen
• Chlorophacinone
• Diphacinone

Historically, the term “superwarfarin” has sometimes been used broadly for anticoagulant rodenticides, although not every anticoagulant rodenticide has the same potency or duration.

LAAR is a more precise clinical term.

Pathophysiology

These agents inhibit vitamin K epoxide reductase (VKOR).

Normally:

Vitamin K epoxide → regenerated active vitamin K → γ-carboxylation of clotting factors

With LAAR poisoning:

VKOR inhibition → failure to regenerate active vitamin K → impaired synthesis of functional vitamin K–dependent proteins

Affected coagulation factors include:

• Factor II
• Factor VII
• Factor IX
• Factor X

Vitamin K–dependent anticoagulant proteins are also affected:

• Protein C
• Protein S
• Protein Z

Why Toxicity Is Delayed

Patients may initially appear completely well because already circulating clotting factors must first be depleted.

Factor VII has a relatively short half-life, so PT/INR becomes abnormal before many other coagulation tests.

Measurable coagulopathy is typically delayed, and clinical bleeding may not appear until several days after exposure. One review found bleeding most commonly occurring approximately 3–9 days after an acute exposure.

This is a major diagnostic pitfall.

Toxic Dose

There is no single reliable toxic dose for all products.

Toxicity depends on:

• Specific anticoagulant
• Concentration of the bait
• Amount ingested
• Acute versus repeated exposure
• Age
• Coingestants
• Baseline anticoagulant therapy

Historical reports suggest that 1–2 mg of brodifacoum can produce anticoagulation in adults.

An evidence-based poison-center guideline suggests that an unintentional ingestion of <1 mg active LAAR ingredient can generally be observed without laboratory testing, whereas asymptomatic exposures of ≥1 mg warrant coagulation testing at approximately 48–72 hours.

The actual active ingredient concentration, rather than the volume of bait alone, is therefore important.

Epidemiology

Most reported exposures are:

• Accidental
• Oral
• In young children

Most small accidental pediatric exposures do not produce clinically important coagulopathy.

Severe poisoning occurs more commonly after:

• Intentional overdose
• Repeated ingestion
• Surreptitious exposure
• Highly concentrated formulations

A review of more than 300,000 reported U.S. exposures found that most were accidental and occurred in children younger than 6 years.

Illicit Drug Contamination

Brodifacoum has also caused large outbreaks after contamination of synthetic cannabinoid products.

During the 2018 U.S. outbreak, patients presented with very high INRs and serious spontaneous bleeding; hematuria was especially common.

Clinical Features

Hematologic

The hallmark is:

Prolonged PT / elevated INR

With severe deficiency:

• aPTT may also become prolonged
• Factors II, VII, IX, and X are reduced

Platelet count and fibrinogen are typically preserved unless another process is occurring.

Bleeding Manifestations

Possible sites include:

HEENT

• Epistaxis
• Gingival bleeding

Dermatologic

• Easy bruising
• Ecchymoses
• Petechiae may occur
• Large hematomas

Genitourinary

Hematuria is particularly common.

Gastrointestinal

• Hematemesis
• Melena
• Hematochezia
• Retroperitoneal hemorrhage

Pulmonary

Rarely:

• Hemoptysis
• Alveolar hemorrhage
• Hemothorax

Musculoskeletal

• Intramuscular hematomas
• Hemarthrosis
• Compartment syndrome from expanding hemorrhage

Reproductive

• Heavy vaginal bleeding
• Menorrhagia

Cardiovascular

Rare but severe:

• Hemopericardium
• Cardiac tamponade

Neurologic

The most feared complication is:

Intracranial hemorrhage

Possible manifestations:

• Severe headache
• Vomiting
• Focal neurologic deficit
• Seizure
• Reduced consciousness
• Coma

Intracranial hemorrhage is an important cause of mortality in severe poisoning.

Hemodynamic Effects

Substantial blood loss may cause:

• Tachycardia
• Hypotension
• Shock

Diagnosis

Think of LAAR poisoning when there is:

Unexplained bleeding + markedly elevated INR + relatively normal platelets/fibrinogen

especially when:

• No therapeutic warfarin use is reported
• Liver disease is absent
• Coagulopathy repeatedly returns after vitamin K treatment

Essential Tests

Obtain:

• PT / INR
• CBC
• Hemoglobin
• Platelets

In significant poisoning also obtain:

• aPTT
• Fibrinogen
• Electrolytes
• BUN
• Creatinine
• Liver-function tests
• Type and screen / crossmatch when bleeding is significant

Coagulation Pattern

Typical LAAR poisoning produces:

↑ PT / INR

and in severe cases:

↑ aPTT

with:

• Normal platelets
• Usually normal fibrinogen

This differentiates it from disorders such as disseminated intravascular coagulation.

Clotting Factor Testing

When the diagnosis is unclear:

• Factors II, VII, IX, and X may be reduced
• Factor V should remain relatively preserved

This distinction can help differentiate vitamin K antagonism from severe hepatic synthetic failure.

Specific LAAR Levels

Brodifacoum and other anticoagulants can be measured using specialized testing, usually LC-MS/MS.

Quantitative testing may:

• Confirm exposure
• Help distinguish covert poisoning
• Help guide duration of vitamin K therapy

However, testing is not rapidly available in many hospitals and should not delay treatment.

Differential Diagnosis

Other causes of prolonged INR or bleeding include:

Toxicologic

• Warfarin
• Other anticoagulants
• Crotalid snake envenomation
• Severe hepatotoxic poisoning

Medical

• Liver failure
• Vitamin K deficiency
• Disseminated intravascular coagulation
• Hemophilia or other factor deficiency
• Acquired factor inhibitors
• Severe malnutrition

A useful clue:

LAAR poisoning → vitamin K–dependent factors low, Factor V preserved

Severe hepatic failure → vitamin K–dependent factors AND Factor V may be reduced

Treatment

1. Resuscitation

Management begins with:

• Airway assessment
• IV access
• Hemodynamic support
• Identification of active bleeding
• Blood-product preparation when necessary

For shock:

• IV isotonic crystalloid as appropriate
• Packed RBC transfusion for clinically significant blood loss

Vitamin K₁ — The Essential Antidotal Therapy

Phytonadione (vitamin K₁) is the key treatment for LAAR-induced coagulopathy.

It allows production of new functional clotting factors despite inhibition of vitamin K recycling.

However:

Vitamin K does not immediately replace already depleted clotting factors.

Therefore, major bleeding requires both vitamin K and rapid factor replacement.

Do Not Give Prophylactic Vitamin K to Patients With a Normal INR

In asymptomatic exposure:

Do not routinely give vitamin K before demonstrating coagulopathy.

Giving vitamin K prophylactically can temporarily normalize or delay INR abnormalities and complicate determination of whether significant poisoning occurred.

Current guidance recommends baseline assessment when indicated and repeat INR approximately 48–72 hours after exposure rather than prophylactic vitamin K.

No Bleeding but Elevated INR

For clinically significant INR elevation without active bleeding:

Oral vitamin K₁ is generally preferred.

One contemporary hospital guideline uses:

Vitamin K₁ 10–20 mg orally when INR is >4 in a patient not taking therapeutic vitamin K antagonists.

However, LAAR poisoning is unusual because very large and prolonged doses may eventually be needed.

Published severe cases frequently require approximately:

50–100 mg/day or more

and reported doses range considerably higher.

There is no universally established optimal dose; therapy should be titrated according to:

• INR
• Clinical bleeding
• Specific LAAR
• Serum LAAR concentration when available
• Toxicology/hematology guidance

Major or Life-Threatening Bleeding

Major hemorrhage requires:

Rapid factor replacement + IV vitamin K₁

Vitamin K₁

A contemporary adult poisoning guideline recommends:

Vitamin K₁ 10 mg IV slowly

for active bleeding due to vitamin K antagonist poisoning.

Subsequent dosing in LAAR poisoning must be individualized because recurrent coagulopathy is common.

Important

IV phytonadione should be administered slowly because hypersensitivity reactions can occur.

Avoid intramuscular injection in a severely coagulopathic patient because of hematoma risk.

Four-Factor Prothrombin Complex Concentrate

For severe or life-threatening bleeding:

4-factor PCC can rapidly replace factors II, VII, IX, and X.

Advantages compared with plasma include:

• Rapid administration
• Small volume
• Rapid INR correction

Direct trials specifically comparing PCC with FFP in LAAR poisoning are lacking, but modern reviews support both for rapid reversal, and evidence from warfarin reversal favors PCC for rapid INR correction.

Fresh Frozen Plasma

If PCC is unavailable or unsuitable:

Fresh frozen plasma (FFP) can replenish vitamin K–dependent clotting factors.

The effect of PCC or FFP is temporary because the LAAR remains in the body.

Therefore:

PCC/FFP must be accompanied by vitamin K₁.

Otherwise coagulopathy will recur.

Why Vitamin K Treatment Lasts So Long

Brodifacoum and related agents are:

• Highly lipophilic
• Strongly retained in tissues/liver
• Slowly eliminated

Reported human brodifacoum elimination half-lives are approximately 15–30 days, with prolonged biological effects.

Consequently:

Vitamin K therapy may be required for weeks to several months.

A 2024 poisoning guideline specifically emphasizes that superwarfarin patients may need vitamin K₁ therapy for several months.

Rebound Coagulopathy

A central principle is:

A normal INR while taking vitamin K does NOT prove that the LAAR has cleared.

Stopping vitamin K too early can cause:

Rebound INR elevation → recurrent spontaneous hemorrhage

One commonly used strategy when specific LAAR levels are unavailable is:

1. Stabilize the patient on oral vitamin K
2. Stop vitamin K when clinically appropriate
3. Repeat PT/INR after approximately 48–72 hours
4. Restart treatment if coagulopathy recurs

Gastrointestinal Decontamination

Do Not Induce Vomiting

The historical recommendation for ipecac is obsolete.

Do not induce vomiting.

Gastric Lavage

Routine gastric lavage is not recommended.

The evidence-based poison-center guideline specifically advises against routine:

• Ipecac
• Gastric lavage

for LAAR exposure.

Activated Charcoal

Activated charcoal may be considered in selected patients after a substantial, very recent intentional ingestion if:

• The airway is intact or protected
• Aspiration risk is low

However, gastrointestinal decontamination is generally not useful after small accidental exposures and should never delay stabilization or transport.

Multiple-Dose Activated Charcoal

Although enterohepatic recirculation has been proposed:

Multiple-dose activated charcoal has not demonstrated reliable clinical benefit and is not routinely recommended.

Cholestyramine

Cholestyramine has been proposed theoretically to interrupt enterohepatic cycling, but evidence is insufficient for routine use.

Hemodialysis

Hemodialysis is generally not useful for removing brodifacoum because these compounds are:

• Highly lipophilic
• Extensively protein/tissue bound
• Associated with a large distribution into tissues

Treatment relies instead on:

• Vitamin K
• Factor replacement
• Supportive care

Monitoring

Acute Exposure

For significant, unknown-dose, deliberate, or chronic exposure:

• Obtain baseline PT/INR
• Repeat PT/INR at approximately 48–72 hours
• Monitor sooner and more frequently if symptoms develop

The 2024 guideline similarly recommends INR at baseline and again approximately 48 hours after ingestion because anticoagulant effects may be delayed.

During Vitamin K Therapy

Monitor:

• PT/INR
• Hemoglobin
• Clinical bleeding
• Renal function when relevant

Severe cases initially require frequent INR testing.

Accidental Pediatric Exposure

Most accidental childhood bait ingestions are small and do not cause clinically important poisoning.

An evidence-based poison-center guideline states:

• <1 mg active ingredient: generally safe for home observation in an asymptomatic accidental exposure
• ≥1 mg or uncertain significant exposure: check coagulation approximately 48–72 hours later

This threshold applies to the amount of active anticoagulant, not grams of bait.

When the product or concentration is unknown, contact a poison center rather than estimating from bait volume alone.

Admission

Hospital admission is indicated for:

• Active bleeding
• Markedly elevated INR
• Hemodynamic instability
• Anemia from hemorrhage
• Intracranial bleeding
• GI or retroperitoneal hemorrhage
• Intentional major ingestion with evolving coagulopathy
• Need for PCC/FFP
• Need for high-dose vitamin K with close monitoring

Severe hemorrhage generally requires ICU-level care.

Disposition

Discharge may be appropriate when:

• Patient is hemodynamically stable
• No active bleeding remains
• Hemoglobin is stable
• A reliable oral vitamin K regimen has been established when required
• Follow-up INR monitoring is guaranteed
• Medication access and adherence are reliable

Intentional exposure also requires appropriate mental-health assessment.

Pregnancy

Maternal coagulopathy can endanger both mother and fetus.

Significant exposure during pregnancy warrants:

• Obstetric consultation
• Maternal INR monitoring
• Assessment for maternal or fetal bleeding when clinically indicated

Human data for individual LAAR agents are limited.

Prognosis

Most small accidental exposures result in no serious complications.

Severe deliberate poisoning can cause:

• Massive hemorrhage
• Intracranial bleeding
• Shock
• Death

However, the anticoagulant effect is highly treatable when recognized and when prolonged vitamin K therapy is maintained.

The most important long-term problem is often recurrent coagulopathy caused by premature discontinuation or poor adherence to vitamin K therapy.

Important Pitfalls

1. Checking INR too early and assuming the patient is safe

The anticoagulant effect is delayed.

A normal initial INR does not exclude significant ingestion.

2. Giving vitamin K prophylactically

Do not routinely give vitamin K when the INR is normal.

It can mask evolving toxicity.

3. Stopping vitamin K when the INR becomes normal

A normal INR while receiving vitamin K does not mean the poison has cleared.

4. Treating major bleeding with vitamin K alone

Vitamin K takes time to restore clotting factors.

Life-threatening bleeding requires:

PCC or FFP + vitamin K₁

5. Treating PCC/FFP as definitive therapy

Factor replacement works only temporarily.

Without ongoing vitamin K, rebound anticoagulation is expected.

6. Missing occult superwarfarin poisoning

Consider LAAR exposure in:

Unexplained bleeding + extremely high INR + normal platelets/fibrinogen

especially when vitamin K correction repeatedly relapses.

7. Missing intracranial bleeding

Severe headache, vomiting, focal deficits, seizure, or reduced consciousness require urgent neuroimaging.

8. Assuming all rat poisons are anticoagulants

Modern rodenticides may instead contain:

• Bromethalin
• Cholecalciferol
• Zinc phosphide
• Other toxicants

The product should be identified whenever possible.

9. Using ipecac or routine gastric lavage

These are obsolete approaches and are not recommended.

High-Yield Toxicology Pearls

Brodifacoum/LAAR poisoning = delayed, prolonged vitamin K antagonist coagulopathy

Think:

Bleeding + very high INR + normal platelets/fibrinogen → consider superwarfarin

Key points:

• Preferred term: long-acting anticoagulant rodenticide (LAAR)
• Mechanism: vitamin K epoxide reductase inhibition
• Factors affected: II, VII, IX, X
• Protein C and S are also affected
• Toxicity is delayed
• Clinical bleeding may appear days after exposure
• Hematuria is a common manifestation
• Intracranial hemorrhage is the most feared complication
• Main laboratory test: PT/INR
• Specific serum LAAR testing can confirm poisoning
• Do not give prophylactic vitamin K when INR is normal
• Elevated INR without bleeding → generally oral vitamin K₁
• Major bleeding → 4-factor PCC or FFP + IV vitamin K₁
• Severe cases often require high-dose vitamin K for weeks to months
• Never stop therapy solely because INR is normal while the patient is still receiving vitamin K
• Recheck INR approximately 48–72 hours after stopping vitamin K
• Routine ipecac, gastric lavage, and multiple-dose charcoal are not recommended
• Hemodialysis does not meaningfully remove brodifacoum
• Most small accidental childhood exposures do well
• Severe intentional poisoning requires prolonged follow-up and meticulous adherence to vitamin K therapy

Toxicology – Botulism

Core concept

Botulism is a life-threatening neuroparalytic illness caused by botulinum neurotoxin.

The characteristic syndrome is:

Cranial nerve palsies → symmetric descending flaccid paralysis → respiratory failure

A particularly important diagnostic clue is:

Descending paralysis with preserved sensation and usually preserved consciousness

Botulinum toxin prevents acetylcholine release from presynaptic cholinergic nerve terminals, producing skeletal-muscle and autonomic paralysis.

Causative Organisms

Botulism is usually caused by toxin produced by Clostridium botulinum, an anaerobic, spore-forming gram-positive organism.

Botulinum neurotoxin may also rarely be produced by:

• Clostridium baratii
• Clostridium butyricum

The traditional botulinum neurotoxin serotypes are:

A, B, C, D, E, F, and G

The older description of “eight strains” reflects historical toxin classification rather than the modern conventional seven-serotype A–G system.

Forms of Botulism

Major clinical forms include:

1. Foodborne botulism

Preformed toxin is ingested in contaminated food.

Classic sources include:

• Improperly home-canned food
• Fermented or preserved foods
• Improperly processed foods
• Certain preserved fish products

Several people who shared the same food may become ill.

2. Infant botulism

Spores are ingested → intestinal colonization → toxin produced within the intestine.

Typical early manifestations include:

• Constipation
• Poor feeding
• Weak cry
• Loss of head control
• Hypotonia

Infants can subsequently develop bulbar weakness and respiratory failure.

3. Wound botulism

Spores contaminate a wound and produce toxin locally.

It is particularly associated with:

• Injection drug use
• Contaminated traumatic wounds

Neurologic manifestations resemble foodborne botulism, but GI prodromal symptoms are usually absent.

4. Adult intestinal colonization botulism

Rarely, the organism colonizes the adult intestine and produces toxin in vivo.

Risk factors may include:

• Altered gastrointestinal anatomy
• Intestinal disease
• Altered intestinal flora

5. Iatrogenic botulism

Can occur after excessive systemic exposure to therapeutic or cosmetic botulinum toxin injections.

6. Inhalational botulism

Extremely rare naturally, but possible with laboratory or intentional aerosol exposure.

Infant Botulism and Honey

Children younger than 12 months should not be given honey, because honey can contain C. botulinum spores.

This includes avoiding honey added to:

• Food
• Water
• Formula
• Pacifiers

Pathophysiology

Botulinum neurotoxin binds irreversibly to presynaptic cholinergic nerve terminals.

It enters the nerve terminal and interferes with the SNARE proteins necessary for acetylcholine-containing vesicles to fuse with the presynaptic membrane.

Therefore:

Botulinum toxin → prevents acetylcholine release → neuromuscular transmission failure → flaccid paralysis

It affects:

• Neuromuscular junctions
• Parasympathetic autonomic terminals
• Other cholinergic autonomic synapses

Recovery requires formation and restoration of functional nerve terminals, explaining why weakness can persist for weeks to months.

Clinical Features

Classic Neurologic Pattern

The classic sequence is:

Cranial nerves first → bulbar muscles → neck/upper extremities → trunk/lower extremities → respiratory muscles

The paralysis is:

• Symmetric
• Descending
• Flaccid
• Generally without sensory loss

CDC emphasizes that botulism typically begins with prominent cranial nerve dysfunction and progresses downward.

Cranial Nerve Findings

Common early manifestations include:

• Diplopia
• Blurred vision
• Ptosis
• Ophthalmoplegia
• Dysarthria
• Dysphonia
• Dysphagia
• Facial weakness

Pupils may become:

• Dilated
• Sluggishly reactive
• Occasionally fixed

Bulbar Dysfunction

Bulbar weakness may cause:

• Difficulty swallowing
• Nasal speech
• Weak gag
• Drooling
• Poor airway protection
• Aspiration

Bulbar weakness is an important warning sign for impending respiratory deterioration.

Respiratory

Progressive respiratory-muscle paralysis may cause:

• Reduced tidal volume
• Dyspnea
• Weak cough
• Inability to clear secretions
• Hypercapnia
• Respiratory failure

Hypoxemia may be a late finding.

Therefore, normal oxygen saturation does not guarantee adequate respiratory muscle function early in the disease.

Autonomic Findings

Botulinum toxin can cause autonomic dysfunction including:

• Dry mouth
• Dry eyes
• Constipation
• Urinary retention
• Ileus
• Orthostatic hypotension
• Blood-pressure variability
• Tachycardia or bradycardia

Mental Status

A classic feature is:

The patient may be profoundly weak or paralyzed while remaining awake and cognitively intact.

This can cause considerable anxiety, particularly in mechanically ventilated patients.

CDC recommends establishing communication systems and providing psychological support for these patients.

Foodborne Botulism

Incubation

Symptoms commonly begin approximately:

12–36 hours after ingestion

but onset can range from several hours to several days depending on toxin dose and other factors.

Gastrointestinal Prodrome

Possible early symptoms include:

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

These are followed by neurologic manifestations.

Not every patient develops prominent GI symptoms.

Infant Botulism

Think of infant botulism when an infant develops:

Constipation + poor feeding + weak cry + hypotonia

Other manifestations include:

• Ptosis
• Sluggish pupils
• Flattened facial expression
• Weak suck
• Weak gag
• Loss of head control
• Generalized “floppiness”
• Respiratory difficulty

Wound Botulism

Clinical manifestations are similar to foodborne disease but typically:

No gastrointestinal prodrome

Examine carefully for:

• Injection sites
• Abscesses
• Necrotic wounds

The external appearance of the wound does not reliably predict whether toxin is being produced.

Diagnosis

Botulism is initially a clinical diagnosis.

Do not wait for laboratory confirmation before treating a patient with clinically suspected progressive botulism.

CDC emphasizes that delays in antitoxin administration can worsen outcomes.

Laboratory Confirmation

Depending on the clinical form, public-health laboratories may test:

• Serum
• Stool
• Gastric contents
• Wound specimens
• Suspected food

Confirmation can involve:

• Detection of botulinum neurotoxin
• Isolation of a botulinum toxin-producing Clostridium species

Whenever possible, serum should be collected before antitoxin, but specimen collection must not delay treatment.

Infant Botulism Testing

For infant botulism, stool is the preferred diagnostic specimen for toxin testing and culture.

Treatment with BabyBIG should not be delayed while waiting for the result.

Differential Diagnosis

Important mimics include:

Neuromuscular

• Guillain-Barré syndrome
• Miller Fisher syndrome
• Myasthenia gravis
• Lambert-Eaton myasthenic syndrome
• Tick paralysis

Toxicologic

• Organophosphate poisoning
• Paralytic shellfish poisoning
• Certain snake envenomations
• Magnesium toxicity
• Neuromuscular-blocking drugs

Neurologic

• Brainstem stroke
• CNS infection
• Poliomyelitis

Botulism is distinguished particularly by:

Prominent cranial neuropathies + symmetric descending paralysis + absence of sensory deficits.

Electrodiagnostic Testing

EMG and nerve-conduction studies can support the diagnosis.

Possible findings include:

• Low-amplitude compound muscle action potentials
• Incremental response with high-frequency repetitive nerve stimulation
• Presynaptic neuromuscular-junction abnormalities

However, electrophysiologic findings may be absent or nonspecific early in disease.

Respiratory Monitoring

This is one of the most important aspects of management.

Monitor serially:

• Respiratory rate
• Work of breathing
• Bulbar function
• Forced vital capacity
• Inspiratory strength
• Expiratory strength
• End-tidal CO₂ when available

Serial measurements are more valuable than a single measurement.

Concerning Respiratory Values

Because specific botulism thresholds are not well validated, CDC notes that thresholds used for other neuromuscular disorders may help guide decisions.

Concerning findings include approximately:

• FVC <20 mL/kg
• Maximum inspiratory pressure / NIF weaker than approximately −30 cm H₂O
• Maximum expiratory pressure <40 cm H₂O

These values should not be used in isolation; worsening bulbar weakness or clinical respiratory fatigue may justify earlier intubation.

Important Pitfall

Do not wait for:

• Hypoxemia
• Severe hypercapnia
• Respiratory arrest

before intubation.

Pulse oximetry and ABG abnormalities can occur late in neuromuscular respiratory failure.

Treatment

1. Airway and Ventilation

Management begins with meticulous assessment of:

• Airway protection
• Swallowing ability
• Respiratory muscle strength

Early endotracheal intubation and mechanical ventilation may be lifesaving.

Some patients require ventilatory support for weeks to months while neuromuscular function recovers.

2. Botulinum Antitoxin

For non-infant botulism, the current U.S. product is:

Botulism Antitoxin Heptavalent (BAT)

It contains antibodies against toxin types:

A, B, C, D, E, F, and G

and is equine-derived.

Mechanism

Antitoxin:

Binds circulating unbound toxin → prevents toxin from reaching additional nerve terminals

It does not remove toxin already internalized into nerve terminals.

Therefore:

Antitoxin stops progression; it does not immediately reverse established paralysis.

Timing

Give antitoxin as early as possible when botulism is clinically suspected.

The greatest benefit occurs when treatment begins within the first 1–2 days, but patients with continuing progression may still benefit later.

Do not wait for laboratory confirmation.

Adult BAT Dose

Current U.S. labeling specifies:

1 vial IV for adults ≥17 years

Pediatric dosing is weight/age based.

Antitoxin Adverse Effects

Because BAT is equine-derived, monitor for:

• Infusion reactions
• Anaphylaxis
• Delayed serum sickness

Routine skin testing before BAT administration is not recommended by current CDC guidance.

Infant Botulism – BabyBIG

Infant botulism is treated differently.

The preferred specific therapy in the United States is:

BabyBIG® — Botulism Immune Globulin Intravenous (Human)

It contains human antibodies against botulinum toxin types A and B and should be administered promptly when the clinical diagnosis is supported.

Treatment should not wait for laboratory confirmation.

Important 2026 Dosing Update

The historical BabyBIG label lists 50 mg/kg.

However, in September 2026, FDA issued a specific dosage change for BabyBIG Lot 8 because that lot has higher antibody titers:

20 mg/kg (0.4 mL/kg) IV once

for Lot 8, superseding the older 50 mg/kg instruction for that lot.

Therefore:

Use the current lot-specific BabyBIG dosing instructions rather than relying on older textbook doses.

Wound Botulism

Management includes:

Antitoxin

Administer BAT promptly when wound botulism is suspected.

Surgical treatment

Debridement of infected or devitalized tissue helps eliminate the source of ongoing toxin production.

Antibiotics

Antibiotics may be appropriate as part of wound management, but antitoxin and debridement remain fundamental.

CDC notes that routine antimicrobials do not treat the circulating neurotoxin itself.

Gastrointestinal Decontamination

The older source recommends:

• Gastric lavage
• Activated charcoal
• Whole-bowel irrigation

These are not routine modern treatments for botulism.

CDC notes that there are no human data demonstrating benefit from activated charcoal, while patients with bulbar weakness are at significant risk of aspiration. There is also no established benefit from polyethylene-glycol bowel-cleansing therapy.

Therefore, treatment should prioritize:

Antitoxin + airway protection + respiratory monitoring

rather than aggressive GI decontamination.

Medications to Use With Caution

Aminoglycosides

Aminoglycosides can impair neuromuscular transmission and may worsen paralysis.

Examples include:

• Gentamicin
• Amikacin
• Tobramycin

They should be used only after careful consideration when clinically necessary.

Magnesium

Magnesium suppresses presynaptic acetylcholine release and may aggravate neuromuscular weakness.

Use cautiously.

Other Agents

CDC also recommends careful consideration with:

• Clindamycin
• Tetracyclines
• Neuromuscular-blocking drugs
• Other medications that impair neuromuscular transmission

Supportive ICU Care

Patients may require prolonged intensive care.

Important measures include:

• Mechanical ventilation
• Aspiration precautions
• Enteral nutritional support
• DVT prophylaxis
• Pressure-injury prevention
• Bladder care
• Bowel management
• Eye lubrication for impaired blinking/dry eyes
• Physical and occupational rehabilitation

CDC specifically emphasizes preventing complications associated with prolonged paralysis and ventilation.

Public Health Management

Botulism is a public-health emergency because:

• Contaminated food may expose multiple people
• Rapid access to antitoxin is required
• Public-health laboratories perform specialized diagnostic testing

In the United States, suspected cases should be reported immediately to the appropriate health department, which coordinates consultation, testing, and antitoxin through CDC.

Admission

All patients with suspected symptomatic botulism should be managed in a hospital capable of close neurologic and respiratory monitoring.

Patients with:

• Bulbar dysfunction
• Progressive weakness
• Respiratory abnormalities

generally require ICU-level observation or care. CDC recommends hospital admission for suspected cases under conventional standards of care.

Prognosis

With modern critical care and antitoxin, mortality has fallen dramatically.

Current mortality is <5%, compared with much higher historical rates.

However, recovery may be prolonged because damaged neuromuscular junctions need time to regenerate.

Patients may require:

• Weeks to months of ventilation
• Rehabilitation
• Nutritional support

Persistent symptoms may include:

• Fatigue
• Weakness
• Exertional dyspnea

for months or occasionally longer.

Important Pitfalls

1. Waiting for laboratory confirmation

Do not delay antitoxin while waiting for toxin assays or cultures.

Clinical suspicion is sufficient to initiate the public-health consultation and treatment process.

2. Waiting for hypoxemia before intubating

Respiratory-muscle failure can be advanced before oxygen saturation falls.

Monitor:

• FVC
• Inspiratory strength
• Bulbar function
• Clinical respiratory effort

3. Assuming antitoxin reverses established paralysis

Antitoxin only neutralizes circulating, unbound toxin.

Established weakness resolves gradually through neuronal recovery.

4. Missing the cranial nerve pattern

Early symptoms such as:

• Diplopia
• Ptosis
• Dysphagia
• Dysarthria

may precede obvious limb weakness.

5. Mistaking botulism for Guillain-Barré syndrome

Botulism characteristically produces:

Cranial nerves first + descending symmetric paralysis + no sensory loss

6. Giving unnecessary magnesium or neuromuscular-blocking drugs

These may worsen weakness.

7. Using the old antitoxin regimen

The historical mono-, bi-, and trivalent antitoxins have been replaced in the United States by:

Heptavalent BAT (A–G) for non-infant botulism.

8. Using the old BabyBIG dose without checking the current lot

As of September 2026, FDA specifies 20 mg/kg for BabyBIG Lot 8, rather than the older 50 mg/kg label dose.

9. Missing infant botulism

Remember:

Constipation may be the first symptom.

Followed by:

• Poor feeding
• Weak cry
• Hypotonia
• Loss of head control

10. Giving honey to an infant

No honey before 12 months of age.

High-Yield Toxicology Pearls

Botulism = cranial nerve palsies + symmetric descending flaccid paralysis

Think:

Diplopia/ptosis → dysarthria/dysphagia → descending weakness → respiratory failure

Key points:

• Mechanism: presynaptic inhibition of acetylcholine release
• Sensation is generally preserved
• Mental status is usually preserved
• Foodborne botulism = preformed toxin ingestion
• Infant botulism = intestinal colonization and toxin production
• Wound botulism = toxin production in contaminated tissue
• Infant clue: constipation + poor feeding + floppy baby
• Do not give honey before 12 months
• Diagnosis is initially clinical
• Do not wait for laboratory confirmation
• Closely monitor respiratory and bulbar function
• Normal pulse oximetry does not exclude impending ventilatory failure
• Main specific treatment for non-infant disease: heptavalent BAT
• BAT prevents progression but does not reverse existing paralysis
• Infant botulism: BabyBIG
• Current BabyBIG Lot 8 dosing: 20 mg/kg IV once
• Wound botulism also requires source control/debridement
• Avoid or use caution with drugs that impair neuromuscular transmission, particularly aminoglycosides and magnesium
• Activated charcoal and bowel irrigation have no established routine benefit
• Respiratory support is the most important life-saving supportive treatment
• Recovery commonly takes weeks to months

Toxicology – Boric Acid and Borates

Core concept

Boric acid and borates are boron-containing compounds used in household, industrial, and pesticide products.

Most isolated accidental ingestions cause little or no systemic toxicity, but substantial or repeated exposure can cause a characteristic multisystem syndrome:

GI irritation → dehydration/metabolic abnormalities → erythematous desquamating rash + CNS toxicity + acute kidney injury

The most clinically important principle is:

Acute single ingestion is often less dangerous than older toxicology texts suggested, whereas repeated exposure—especially in infants or patients with renal impairment—can produce severe toxicity.

A poison-center series of 784 ingestions found no severe toxicity and found that 88% of patients were asymptomatic.

Forms and Uses

Boric acid

Usually encountered as:

• White powder
• Crystals
• Granules
• Solutions

Borax

Borax = sodium tetraborate, usually encountered as:

• Sodium tetraborate decahydrate
• Sodium tetraborate pentahydrate
• Anhydrous sodium tetraborate

Common uses include:

• Household cleaning products
• Ant and cockroach insecticides
• Wood preservatives
• Glass and ceramic manufacture
• Glazes and enamels
• Fire-resistant materials
• Industrial cleaning compounds

Boron is also naturally present in:

• Food
• Water
• Soil

Routes of Exposure

Potential routes include:

• Ingestion
• Dermal exposure
• Eye exposure
• Inhalation of dust

Systemic toxicity is most important after oral exposure.

Boron is absorbed through the gastrointestinal tract and is eliminated predominantly through the kidneys. More than 90% of an absorbed dose may ultimately be excreted in urine.

Toxic Dose

There is no reliably defined human toxic dose.

Historical estimates suggested minimum lethal oral doses of approximately:

• Adults: 5–20 g
• Children: 3–6 g
• Infants: <5 g

However, these estimates should be interpreted cautiously because human dose-response relationships are extremely variable.

Large clinical series have demonstrated patients remaining asymptomatic after surprisingly large acute ingestions, and serum concentrations correlate poorly with clinical severity.

Therefore:

Do not use dose alone to predict severity.

Consider:

• Amount
• Concentration
• Acute versus repeated exposure
• Age
• Clinical symptoms
• Renal function

High-Risk Patients

Greater concern is warranted in:

• Infants
• Young children
• Patients with renal impairment
• Repeated/chronic exposure
• Large intentional ingestion
• Significant dehydration

Reduced renal clearance can prolong systemic exposure and substantially increase toxicity. A 2026 case demonstrated clinically important toxicity after approximately 6 g in an older patient with chronic kidney disease.

Pathophysiology

The precise cellular mechanism of severe boric acid toxicity remains incompletely understood.

Important toxicokinetic features include:

• Efficient GI absorption
• Relatively little metabolism
• Predominantly renal elimination
• Prolonged exposure when kidney function is impaired

Major target systems include:

• Gastrointestinal tract
• Skin
• Central nervous system
• Kidneys

Clinical Features

Gastrointestinal Toxicity

The most common manifestations of acute ingestion are:

• Nausea
• Vomiting
• Abdominal pain
• Diarrhea

Vomitus or diarrhea has classically been described as blue-green, although this finding is neither sensitive nor required for diagnosis.

Severe cases may cause:

• Hematemesis
• Hematochezia
• Severe fluid loss
• Dehydration

Large poison-center series confirm that vomiting, abdominal pain, and diarrhea are the most common manifestations after acute ingestion.

Dermatologic Toxicity

A classic severe manifestation is a diffuse erythematous eruption sometimes described as:

“Boiled lobster” rash

This may progress to:

• Generalized erythema
• Desquamation
• Exfoliation

Severe historical cases can resemble extensive exfoliative dermatitis.

NPIC describes extreme exposures producing a red skin eruption followed by skin loss.

Neurologic

Severe poisoning may cause:

• Irritability
• Headache
• Confusion
• Abnormal movements
• Tremor
• Altered mental status
• Seizures
• Coma

Neurologic toxicity has been particularly described after large or repeated exposure in infants.

Renal

Possible manifestations include:

• Elevated creatinine
• Oliguria
• Acute kidney injury
• Rarely anuric renal failure

Renal dysfunction is especially important because:

Reduced elimination → greater boric acid accumulation → worsening toxicity

This can create a cycle of progressive exposure in patients with pre-existing or newly developing renal impairment.

Fluids, Electrolytes, and Acid-Base

Severe vomiting and diarrhea may cause:

• Dehydration
• Hypernatremia
• Hyperchloremia
• Electrolyte abnormalities
• Metabolic acidosis

Severe systemic illness may further worsen metabolic acidosis.

HEENT

Exposure may cause:

• Oral or mucous-membrane irritation
• Eye irritation
• Conjunctivitis

Borax dust can also produce:

• Dry nose and throat
• Sore throat
• Epistaxis

Pulmonary

Inhalation of borate dust may cause:

• Cough
• Throat irritation
• Dyspnea
• Upper respiratory tract irritation

NIOSH lists the respiratory tract, eyes, and skin among the principal targets of occupational sodium borate exposure.

Diagnosis

Diagnosis is primarily based on:

Exposure history + characteristic gastrointestinal, dermatologic, neurologic, or renal findings

No single laboratory value reliably determines severity.

Laboratory Investigations

Mild/asymptomatic exposure

Extensive laboratory testing is generally unnecessary.

Significant or symptomatic exposure

Consider:

• Serum electrolytes
• Bicarbonate
• BUN
• Creatinine
• Glucose
• Blood gas
• Urinalysis

In intentional overdose also consider:

• Acetaminophen concentration
• Salicylate concentration
• Relevant coingestants

Serum Boron / Boric Acid Concentrations

Specialized laboratories can measure:

• Serum boron
• Serum boric acid

These concentrations can confirm exposure but:

They correlate poorly with clinical toxicity.

In the 784-patient series, several patients with substantially elevated concentrations remained entirely asymptomatic.

Therefore, treatment should be guided primarily by:

• Clinical condition
• Renal function
• Estimated exposure
• Evolution of symptoms

rather than a single concentration.

Treatment

1. Supportive Care

There is no specific antidote.

Treatment centers on:

• Airway and breathing support
• IV fluids when needed
• Correction of electrolyte abnormalities
• Management of seizures
• Renal support
• Treatment of shock

2. Fluid Resuscitation

Vomiting and diarrhea may cause substantial volume depletion.

Use isotonic crystalloid to:

• Restore intravascular volume
• Maintain renal perfusion
• Correct dehydration

Fluid administration should be individualized, particularly if acute kidney injury develops.

The historical recommendation to force urine output to a specific target should not be applied rigidly.

Gastrointestinal Decontamination

Do Not Induce Vomiting

The historical recommendation for ipecac-induced emesis is obsolete.

Do not administer ipecac and do not induce vomiting.

Activated Charcoal

Activated charcoal is not routinely recommended for isolated boric acid ingestion.

Boric acid binds poorly to activated charcoal; experimentally, impractically large charcoal doses would be required for meaningful adsorption.

Gastric Lavage

Routine gastric lavage is also not recommended in contemporary poisoning management.

For most acute exposures:

Supportive care and clinical observation are preferable to aggressive GI decontamination.

A large clinical series concluded that aggressive treatment is unnecessary in most single acute boric acid ingestions.

Skin Exposure

For dry powder:

• Remove contaminated clothing
• Brush or wipe off excess dry material first when practical
• Wash thoroughly with water and soap

For liquid exposure:

• Irrigate exposed skin thoroughly with water

Extensive exposure through damaged skin deserves greater attention because intact skin is a better barrier than compromised skin.

Eye Exposure

Immediately irrigate with:

• Water
• Normal saline

Persistent:

• Pain
• Redness
• Photophobia
• Visual disturbance

requires further ocular evaluation.

Inhalation

• Remove from exposure
• Move to fresh air
• Provide respiratory support if necessary

Persistent cough or dyspnea warrants medical assessment.

Seizures

Treat seizures according to standard toxicologic seizure management, generally beginning with:

Benzodiazepines

while correcting:

• Hypoxia
• Glucose abnormalities
• Electrolyte abnormalities
• Significant acidosis

Hemodialysis

Boric Acid Is Dialyzable

Boric acid has properties favorable for extracorporeal removal:

• Small molecular size
• Predominantly renal elimination
• Relatively low volume of distribution

Hemodialysis can markedly increase elimination.

One pharmacokinetic study reduced the serum boric acid half-life from approximately 13.5 hours to 3.8 hours during hemodialysis.

When to Consider Hemodialysis

Dialysis is not required for most isolated acute ingestions.

Consider it in severe poisoning, especially with:

• Significant acute kidney injury
• Pre-existing renal impairment
• Severe neurologic toxicity
• Hemodynamic deterioration
• Severe metabolic abnormalities
• Very large exposure with significant symptoms
• Persistent high systemic burden with impaired elimination

Recent reports continue to support extracorporeal therapy in severe poisoning, particularly when renal function is impaired.

Continuous Renal Replacement Therapy

When severe toxicity coexists with hemodynamic instability, continuous hemodiafiltration/continuous renal replacement therapy may be considered when intermittent hemodialysis is poorly tolerated.

Peritoneal Dialysis

Older reports used peritoneal dialysis.

Modern extracorporeal treatment, when required, generally favors hemodialysis or appropriate continuous renal replacement therapy because clearance is more predictable.

Exchange Transfusion

Exchange transfusion is primarily a historical therapy and is not routine contemporary management.

Antidote

There is no specific antidote for boric acid or borate poisoning.

Management consists of:

Stop exposure + supportive care + correct fluid/electrolyte abnormalities + dialysis for selected severe cases

Occupational Exposure

Sodium Tetraborate – Anhydrous

NIOSH REL:

1 mg/m³ TWA

The current NIOSH Pocket Guide lists no specific current OSHA PEL for this material.

Sodium Tetraborate – Pentahydrate

NIOSH REL:

1 mg/m³ TWA

Again, the current NIOSH Pocket Guide lists no specific OSHA PEL.

Sodium Tetraborate – Decahydrate

NIOSH REL:

5 mg/m³ TWA.

The older source’s statement that OSHA has a 10 mg/m³ PEL for these sodium borates should not be treated as a current specific OSHA standard. The historical rule establishing such limits was later remanded.

Monitoring

Patients with significant toxicity should have serial monitoring of:

• Mental status
• Vital signs
• Fluid balance
• Electrolytes
• Bicarbonate
• BUN
• Creatinine
• Urine output

Severe cases may additionally require:

• Continuous cardiorespiratory monitoring
• Serial blood gases
• Serial boron concentrations when available and clinically useful

Admission

Hospital admission is appropriate for:

• Persistent vomiting or diarrhea
• Significant dehydration
• Electrolyte abnormalities
• Metabolic acidosis
• Acute kidney injury
• Altered mental status
• Seizures
• Significant skin manifestations
• Hemodynamic instability
• Substantial repeated exposure

Severe neurologic, renal, or hemodynamic toxicity warrants ICU-level care.

Prognosis

Most single acute ingestions have a favorable prognosis.

The large poison-center series found:

• 88.3% completely asymptomatic
• No severe toxicity among 784 cases
• GI symptoms as the predominant clinical manifestations

Severe poisoning is more likely after:

• Repeated exposure
• Large exposure
• Infant exposure
• Renal impairment

Recovery may be prolonged if:

• Acute kidney injury develops
• Severe neurologic toxicity occurs
• Significant tissue injury develops

Important Pitfalls

1. Assuming a few grams is automatically lethal

Older texts frequently describe surprisingly low lethal doses.

Modern clinical data demonstrate wide variability, and many substantial single acute ingestions produce only mild or no symptoms.

The patient should be managed according to clinical findings and risk factors, not historical dose thresholds alone.

2. Underestimating repeated exposure

Historically severe and fatal cases frequently involved:

Repeated administration, particularly in infants

rather than a single accidental taste.

3. Missing renal impairment

Because boron is predominantly renally eliminated:

Renal dysfunction can substantially prolong toxicity.

4. Using activated charcoal

Boric acid is poorly adsorbed by activated charcoal, so routine charcoal is not useful.

5. Using ipecac

Ipecac-induced vomiting is obsolete and should not be used.

6. Relying on serum boron concentration

Serum values may confirm exposure but correlate poorly with clinical severity.

7. Missing the characteristic skin syndrome

Severe poisoning may produce:

Diffuse erythema → “boiled lobster” appearance → desquamation

High-Yield Toxicology Pearls

Boric acid/borates = GI toxicity + rash + CNS toxicity + renal injury

Think:

Repeated/large exposure + vomiting/diarrhea + red desquamating rash + AKI ± CNS changes

Key points:

• Boric acid is absorbed orally and eliminated mainly through the kidneys
• Most single acute accidental ingestions cause minimal or no systemic toxicity
• Repeated exposure can be much more dangerous
• Infants and patients with renal impairment are higher risk
• Common acute symptoms: vomiting, abdominal pain, diarrhea
• Classic severe skin finding: “boiled lobster” erythema with desquamation
• Severe toxicity may cause seizures, coma, metabolic acidosis, and AKI
• Serum boron concentrations correlate poorly with severity
• No specific antidote
• Do not induce vomiting
• Activated charcoal is not routinely useful
• Routine gastric lavage is not recommended
• Main treatment: supportive care and fluid/electrolyte management
• Hemodialysis can markedly enhance elimination and should be considered in selected severe cases, especially with renal impairment
• NIOSH REL for sodium tetraborate:
• Anhydrous: 1 mg/m³ TWA
• Pentahydrate: 1 mg/m³ TWA
• Decahydrate: 5 mg/m³ TWA

Toxicology – Black Widow Spider

Core concept

Black widow spider envenomation causes a painful neurotoxic syndrome known as latrodectism.

The characteristic syndrome is:

Painful bite → spreading muscle pain and spasm → autonomic hyperactivity

Typical systemic findings include:

• Severe muscle cramping
• Abdominal or back pain
• Diaphoresis
• Hypertension
• Tachycardia
• Nausea and vomiting

Most patients recover completely, and death is very rare. A large U.S. poison-center review cited by Poison Control found no deaths among more than 15,000 reported exposures.

Important Species

Clinically important Latrodectus spiders include:

• Latrodectus mactans – black widow
• Latrodectus hesperus – western black widow
• Other Latrodectus species in North America and elsewhere
• Latrodectus hasselti – Australian redback spider

The older source incorrectly groups some brown and red widow species under L. hesperus; these are distinct taxa.

Toxic Dose

A single envenomating bite can produce clinically important toxicity.

Severity is influenced by:

• Amount of venom injected
• Patient size
• Age
• Underlying cardiovascular or pulmonary disease

Children and older adults may experience more severe systemic effects.

Pathophysiology

The major venom component is α-latrotoxin.

It causes massive presynaptic neurotransmitter release, including:

• Acetylcholine
• Norepinephrine
• Other neurotransmitters

The result is:

Excess neurotransmitter release → painful skeletal muscle contraction + autonomic hyperactivity

This produces the characteristic combination of:

• Muscle spasm
• Severe pain
• Hypertension
• Tachycardia
• Sweating

Clinical Features

Local Findings

The bite may initially cause:

• Immediate or rapidly developing pain
• Mild erythema
• Small puncture marks
• Local swelling
• Local diaphoresis

The local wound is often relatively unimpressive compared with the severity of systemic pain.

Latrodectism

Pain typically spreads from the bite site to larger muscle groups over approximately 30 minutes to several hours.

For example:

Arm bite → shoulder/chest pain

or

Leg bite → thigh/buttock/abdominal pain

This migration of severe muscle pain and spasm is highly suggestive.

Musculoskeletal

Characteristic findings include:

• Severe muscle cramps
• Painful spasms
• Abdominal-wall rigidity
• Back pain
• Chest-wall pain

The abdomen may become boardlike, creating a presentation that resembles an acute surgical abdomen.

Rarely:

• Rhabdomyolysis may occur

Autonomic Findings

Common manifestations include:

• Diaphoresis
• Hypertension
• Tachycardia
• Restlessness
• Anxiety

Sweating may sometimes be strikingly localized near the bite.

Gastrointestinal

Common symptoms include:

• Nausea
• Vomiting
• Abdominal pain
• Abdominal cramping

Abdominal rigidity may mimic:

• Appendicitis
• Peritonitis
• Other acute abdominal emergencies

Cardiovascular

Possible effects include:

• Hypertension
• Tachycardia

Rare severe complications include:

• Dysrhythmias
• Myocardial injury
• Myocarditis
• Ischemia-like chest pain

An ECG is appropriate when significant hypertension or chest pain occurs.

Pulmonary

Possible manifestations include:

• Tachypnea
• Dyspnea
• Respiratory distress

True respiratory failure is uncommon but has been reported.

Neurologic

Possible findings include:

• Headache
• Anxiety
• Restlessness
• Paresthesias
• Weakness
• Hyperreflexia

Children may present less specifically with:

• Irritability
• Agitation
• Drowsiness
• Abdominal pain

Diagnosis

Diagnosis is primarily clinical.

Think of:

Compatible exposure + severe spreading muscle pain/spasm + diaphoresis/autonomic findings

The spider does not need to be captured or identified for diagnosis.

Differential Diagnosis

Important mimics include:

• Acute surgical abdomen
• Myocardial ischemia
• Renal colic
• Biliary disease
• Pancreatitis
• Sickle-cell crisis
• Tetanus
• Other causes of severe muscle cramping

Upper-extremity bites may produce chest pain that resembles myocardial ischemia.

Laboratory Testing

No specific laboratory test confirms routine black widow envenomation.

Mild cases

Laboratory testing is often unnecessary.

Significant systemic toxicity

Consider:

• CBC
• Electrolytes
• Renal function
• Glucose
• Creatine kinase
• Urinalysis

Possible nonspecific abnormalities include leukocytosis and occasionally elevated CK or evidence of muscle injury.

Additional Testing

Chest pain or significant hypertension

• ECG
• Cardiac assessment as clinically indicated

Prolonged severe muscle spasm

• CK
• Renal function
• Urinalysis

Respiratory distress

• Pulse oximetry
• Blood gas when indicated

Severe abdominal presentation

Appropriate evaluation may be necessary to exclude a genuine surgical abdomen.

Treatment

1. Initial Care

Treatment begins with:

• Airway and breathing assessment
• Vital-sign monitoring
• Local wound cleaning
• Appropriate tetanus prophylaxis
• Analgesia

Routine incision, suction, or other invasive local treatment is not indicated.

2. Mild Envenomation

For pain confined largely to the bite region:

• Oral analgesics
• Local wound care
• Observation for progression

Most mild cases are self-limited.

3. Moderate to Severe Envenomation

For severe spreading pain and muscle spasm:

Opioid analgesia

Opioids are effective for severe pain and can be titrated to clinical response.

Benzodiazepines

Benzodiazepines may be used for:

• Severe muscle spasm
• Agitation associated with systemic envenomation

Because combining opioids and benzodiazepines increases the risk of respiratory depression, patients receiving both require appropriate monitoring.

Calcium Gluconate

Older toxicology texts frequently recommended IV calcium gluconate.

Current evidence indicates:

Calcium gluconate is not reliably effective for latrodectism and is no longer routinely recommended.

Methocarbamol

Similarly:

Methocarbamol is not considered reliably effective and is not routinely recommended.

Antivenom

Role

Black widow antivenom can produce rapid improvement in:

• Severe pain
• Muscle spasm
• Systemic symptoms

In the United States, Antivenin (Latrodectus mactans) (Equine) remains an FDA-licensed biologic.

However, availability may vary between hospitals, and Poison Control notes that it is used relatively rarely.

When to Consider Antivenom

Antivenom is generally reserved for significant systemic envenomation, especially when there is:

• Severe persistent pain despite adequate analgesia
• Severe muscle spasm
• Significant autonomic toxicity
• Respiratory compromise
• Serious cardiovascular effects

It may also be considered when severe symptoms cannot be adequately controlled with supportive therapy.

U.S. Antivenom Dose

The current U.S. product label specifies:

Adults and children: entire contents of one reconstituted single-dose vial

For severe cases, IV administration is preferred:

One vial diluted in 10–50 mL saline and administered IV over approximately 15 minutes.

One vial is usually sufficient, although a second dose may occasionally be necessary.

Antivenom administration should follow the specific product labeling and local poison-center/toxicology guidance.

Antivenom Adverse Effects

Because the U.S. product is equine-derived, adverse reactions may include:

• Immediate hypersensitivity
• Anaphylaxis
• Delayed serum sickness

The manufacturer recommends monitoring for serum sickness in the following days after treatment.

A negative hypersensitivity skin test does not guarantee that an allergic reaction will not occur.

Therefore, antivenom should be given where:

• Airway management is immediately available
• Epinephrine and anaphylaxis treatment are available
• The patient can be appropriately monitored

Pregnancy

Black widow envenomation during pregnancy raises concern because severe pain, muscle spasm, and autonomic effects could potentially affect uterine activity.

However, reported pregnancy outcomes are generally favorable.

Management should prioritize:

• Maternal stabilization
• Adequate analgesia
• Treatment of significant systemic toxicity
• Obstetric assessment when clinically appropriate

Symptomatic pregnant patients may warrant closer observation.

Monitoring

Patients with significant systemic symptoms should have:

• Repeated vital signs
• Respiratory monitoring
• Cardiac monitoring when cardiovascular toxicity is present
• Serial pain and neurologic assessment

Patients receiving:

• Opioids plus benzodiazepines
• Antivenom

require particularly close monitoring.

Admission

Hospital admission should be considered for:

• Persistent severe pain despite treatment
• Significant hypertension
• Cardiovascular complications
• Respiratory distress
• Severe vomiting/dehydration
• Significant systemic toxicity
• Need for repeated parenteral analgesia
• Complications such as rhabdomyolysis

ICU care may be required for severe cardiopulmonary toxicity.

Disposition

A fixed observation period is less important than the clinical course.

Patients may be discharged when:

• Pain is adequately controlled
• Muscle spasm is improving
• Vital signs are stable
• No progressive systemic toxicity is present
• Oral intake and mobility are adequate

Mild cases may improve rapidly; significant latrodectism can persist considerably longer.

Expected Course and Prognosis

Symptoms generally peak within the first several hours.

Most patients improve substantially within:

24–48 hours

although:

• Muscle soreness
• Fatigue
• Weakness
• Residual pain

may persist for several days or occasionally longer.

Permanent sequelae are unusual.

Important Pitfalls

1. Mistaking latrodectism for an acute abdomen

Severe abdominal muscle spasm may create striking rigidity.

A careful history and examination are essential.

2. Missing cardiac disease

Chest pain after an upper-extremity bite may mimic ischemia, but genuine myocardial disease must still be excluded when clinically appropriate.

3. Using calcium gluconate routinely

Older sources commonly recommended calcium.

Current evidence does not support routine calcium gluconate for pain or spasm.

4. Undertreating pain

Severe latrodectism can be extraordinarily painful.

Adequate opioid analgesia and appropriate treatment of muscle spasm are central to supportive care.

5. Combining opioids and benzodiazepines without monitoring

The combination can cause respiratory depression.

6. Forgetting antivenom hypersensitivity

Equine-derived antivenom can cause:

• Anaphylaxis
• Serum sickness

7. Assuming the bite site must look dramatic

The local wound may be subtle despite severe systemic toxicity.

High-Yield Toxicology Pearls

Black widow bite = painful muscle spasm + autonomic hyperactivity

Think:

Bite → spreading pain → abdominal/back muscle spasm + sweating + hypertension

Key points:

• Syndrome: latrodectism
• Major toxin: α-latrotoxin
• Mechanism: massive presynaptic neurotransmitter release
• Severe muscle pain and cramping may begin within minutes to hours
• Abdominal rigidity may mimic an acute surgical abdomen
• Diaphoresis, hypertension, and tachycardia are characteristic
• Routine laboratory testing is unnecessary in mild cases
• Main treatment: analgesia + supportive care
• Opioids are used for severe pain
• Benzodiazepines may help significant muscle spasm
• Calcium gluconate is no longer routinely recommended
• Methocarbamol is not reliably effective
• Antivenom can rapidly improve severe or refractory symptoms
• U.S. antivenom is equine-derived and carries anaphylaxis/serum-sickness risk
• U.S. labeled dose: one vial, with IV administration preferred in severe cases
• Death is very rare
• Most patients recover completely

Toxicology – Bismuth

Core concept

Bismuth toxicity is uncommon and usually occurs after excessive or prolonged exposure rather than a single therapeutic dose.

The most important toxic syndromes are:

Acute/high-dose bismuth exposure → nephrotoxicity

Chronic excessive exposure → encephalopathy

With bismuth subsalicylate, always remember a second toxic component:

Salicylate toxicity may occur independently of bismuth toxicity.

Renal impairment increases the risk of bismuth accumulation and adverse effects.

Forms

Bismuth compounds include:

• Bismuth subsalicylate
• Bismuth subcitrate
• Bismuth subcarbonate
• Bismuth subgallate
• Bismuth subnitrate
• Other inorganic and organic bismuth salts

The most familiar OTC preparation is bismuth subsalicylate.

Current Pepto-Bismol formulations contain 262 mg bismuth subsalicylate per caplet or 525 mg per 30 mL dose, depending on formulation.

Uses

Bismuth-containing products are used for:

• Diarrhea
• Traveler’s diarrhea
• Dyspepsia
• Nausea
• Indigestion
• Combination therapy for Helicobacter pylori

Toxic Dose

There is no single well-established toxic dose applicable to all bismuth compounds.

Toxicity depends on:

• Chemical form
• Solubility
• Duration of exposure
• Renal function
• Dose
• Route of administration

Single therapeutic ingestions rarely cause major bismuth toxicity.

Significant poisoning is more often associated with:

• Chronic excessive use
• Large intentional ingestion
• Renal impairment
• Historically, parenteral bismuth preparations

Pathophysiology

Bismuth absorption varies greatly according to the compound.

Many medicinal bismuth salts are poorly absorbed from the gastrointestinal tract, but the absorbed fraction may:

• Accumulate in tissues
• Concentrate in the kidney
• Persist for prolonged periods

Bismuth has been detected in:

• Kidneys
• Nervous tissue
• Bone
• Liver

The kidney is particularly important because absorbed bismuth is largely handled through renal elimination. Patients with impaired renal function may therefore accumulate higher concentrations.

Bismuth Subsalicylate

Bismuth subsalicylate produces two clinically distinct potential problems:

1. Bismuth toxicity

May cause:

• Encephalopathy
• Nephrotoxicity

2. Salicylate toxicity

May cause:

• Tinnitus
• Tachypnea
• Vomiting
• Acid-base abnormalities
• Altered mental status
• Pulmonary edema
• Severe metabolic toxicity

Bismuth subsalicylate is a recognized source of salicylate poisoning, particularly with chronic excessive use.

Clinical Features

Gastrointestinal

Possible effects include:

• Nausea
• Vomiting
• Diarrhea
• Abdominal discomfort

Black tongue and stool

Bismuth commonly causes a temporary darkening of the tongue and stool.

This is generally harmless and is specifically described in current product labeling.

This benign effect must be distinguished from:

• Melena
• Gastrointestinal bleeding

HEENT

Chronic toxicity has historically been associated with:

• Increased salivation
• Gingivitis
• Stomatitis
• Bluish gingival discoloration

These findings are now uncommon.

Tinnitus

With bismuth subsalicylate, ringing in the ears or hearing changes may indicate clinically significant salicylate exposure.

Current OTC labeling advises stopping the drug and seeking medical advice if tinnitus or hearing loss occurs.

Neurologic

Chronic excessive bismuth exposure can produce bismuth encephalopathy.

Early manifestations may include:

• Malaise
• Headache
• Irritability
• Reduced concentration
• Memory disturbance
• Confusion

Progressive toxicity may produce:

• Dysarthria
• Ataxia
• Gait disturbance
• Tremor
• Myoclonus
• Hallucinations
• Somnolence
• Seizures
• Severe encephalopathy

Chronic bismuth exposure has repeatedly been associated with neurologic toxicity, especially when renal function is impaired.

Renal

The kidney is a major target of significant bismuth toxicity.

Possible abnormalities include:

• Proteinuria
• Hematuria
• Acute tubular injury
• Fanconi-type proximal tubular dysfunction
• Oliguria
• Anuria
• Acute kidney injury

A systematic review of reported human toxicity found kidney injury predominantly after medically related excessive exposures and noted worse outcomes in patients with pre-existing renal dysfunction.

Hepatic

Rare reported effects include:

• Elevated transaminases
• Hepatic dysfunction

Severe liver toxicity is much less characteristic than neurologic or renal injury.

Musculoskeletal

Historical chronic exposure has been associated with:

• Bone deposition
• Osteoarthropathy
• Osteomalacia

These manifestations are uncommon with contemporary therapeutic use.

Hematologic

Some unusual bismuth compounds may indirectly contribute to oxidative or nitrate-related toxicity.

However, with bismuth subsalicylate, the more clinically important hematologic/toxicologic concern is usually the salicylate component rather than direct hematologic toxicity from bismuth.

Diagnosis

Clinical Diagnosis

Think of bismuth toxicity when there is:

Prolonged bismuth use + altered mental status or neurologic abnormalities ± renal dysfunction

For bismuth subsalicylate, also consider:

Chronic OTC use + tinnitus/tachypnea/confusion → salicylate toxicity

Essential Investigations

For symptomatic or significantly exposed patients consider:

• Serum electrolytes
• Bicarbonate
• BUN
• Creatinine
• Glucose
• Urinalysis
• Liver enzymes
• CBC

Salicylate Level

A serum salicylate concentration is essential when bismuth subsalicylate toxicity is suspected.

Remember that chronic salicylate toxicity can be severe at concentrations lower than those seen in acute overdose, so the number must be interpreted together with:

• Symptoms
• Acid-base status
• Renal function
• Timing of exposure

Blood Gas

Obtain a blood gas when significant salicylate toxicity is suspected.

Typical salicylate poisoning may produce:

• Respiratory alkalosis
• Metabolic acidosis
• Mixed acid-base disturbances

Bismuth Concentration

Blood or urine bismuth concentrations can help confirm excessive exposure.

However:

Bismuth levels correlate imperfectly with clinical severity and should not replace clinical assessment.

Testing often requires a specialized reference laboratory.

Differential Diagnosis

For encephalopathy consider:

• Salicylate poisoning
• Lead poisoning
• Mercury poisoning
• Medication toxicity
• Uremia
• Hepatic encephalopathy
• CNS infection
• Structural neurologic disease

For renal injury consider:

• Other heavy metals
• Nephrotoxic medications
• Ischemic acute tubular injury
• Glomerular disease
• Other causes of Fanconi syndrome

Treatment

1. Stop Bismuth Exposure

Immediately discontinue the bismuth-containing product.

This is the most important intervention in chronic toxicity.

Also identify:

• Duration of exposure
• Daily dose
• Exact formulation
• Other salicylate-containing products
• Renal disease
• Coingestants

2. Supportive Care

Provide:

• Airway support when necessary
• IV fluids when appropriate
• Electrolyte correction
• Seizure treatment
• Renal support

Management should be guided by the dominant syndrome:

• Bismuth neurotoxicity
• Renal failure
• Salicylate poisoning

Gastrointestinal Decontamination

Do Not Induce Vomiting

The historical recommendation to use ipecac-induced emesis is obsolete.

Do not induce vomiting.

Activated Charcoal

Activated charcoal may be considered after a significant recent acute ingestion, particularly when salicylate-containing bismuth preparations are involved, provided:

• The airway is protected
• Aspiration risk is acceptable

Activated charcoal has a more established role for the salicylate component than for systemic bismuth already absorbed.

Gastric Lavage

Routine gastric lavage is not recommended in contemporary poisoning management.

It would only be considered in exceptional circumstances after specialist toxicology consultation.

Salicylate Toxicity from Bismuth Subsalicylate

When salicylate poisoning is clinically significant, treatment follows standard salicylate-poisoning principles.

Volume and Electrolyte Correction

Correct:

• Dehydration
• Potassium abnormalities
• Glucose abnormalities

Adequate intravascular volume and renal perfusion are important for salicylate elimination.

Sodium Bicarbonate

For clinically important salicylate poisoning:

IV sodium bicarbonate is used to alkalinize serum and urine and enhance salicylate elimination.

Urinary alkalinization significantly increases renal salicylate clearance.

Hemodialysis

Hemodialysis may be required for severe salicylate poisoning, particularly with:

• Severe neurologic toxicity
• Pulmonary edema
• Significant acidemia
• Renal failure
• Deterioration despite appropriate therapy

Hemodialysis for Bismuth

Hemodialysis has also been used in severe bismuth poisoning associated with acute kidney injury.

However, bismuth may redistribute from tissue stores back into blood after dialysis, so reduction in circulating concentrations may be transient.

Dialysis is therefore most clearly indicated when there are conventional indications such as:

• Severe renal failure
• Electrolyte disturbances
• Acid-base abnormalities
• Severe associated salicylate toxicity

Chelation Therapy

Older references recommend:

• Dimercaprol (BAL)
• D-penicillamine

These are not established routine antidotes for contemporary bismuth poisoning.

Various chelators, including sulfur-containing compounds such as DMPS, have been described in individual cases, but the evidence base consists largely of case reports rather than controlled clinical data.

Therefore:

Chelation should only be considered in severe confirmed bismuth poisoning with medical-toxicology consultation.

Antidote

There is no universally accepted specific antidote for bismuth toxicity.

Treatment is primarily:

• Cessation of exposure
• Supportive care
• Management of renal failure
• Treatment of accompanying salicylate toxicity

Monitoring

For clinically significant toxicity monitor:

• Mental status
• Renal function
• Electrolytes
• Acid-base status
• Urine output

With bismuth subsalicylate exposure also monitor:

• Serial salicylate concentrations
• Respiratory status
• Glucose
• Potassium

Admission

Hospital admission is appropriate for:

• Altered mental status
• Encephalopathy
• Significant renal dysfunction
• Severe salicylate toxicity
• Acid-base disturbance
• Seizures
• Persistent vomiting
• Other clinically significant systemic effects

Severe neurologic or metabolic toxicity may require ICU management.

Pediatric Considerations

Because bismuth subsalicylate contains salicylate, special caution is required in children and adolescents.

Current product labeling states that:

Children and teenagers who have or are recovering from chickenpox or influenza-like illness should not use bismuth subsalicylate because of the risk of Reye syndrome.

Thus, the older blanket statement that it must always be avoided in everyone under age 16 is less precise than current U.S. labeling.

Drug Interactions and Precautions

Current labeling advises against concurrent use in patients:

• Allergic to aspirin or salicylates
• Taking other salicylate products

Medical or pharmacist review is advised when patients are taking drugs for:

• Anticoagulation
• Diabetes
• Gout
• Arthritis

Prognosis

Most therapeutic exposures do not cause serious toxicity.

With significant poisoning:

• Acute kidney injury may take days to weeks to recover
• Severe renal failure may require prolonged dialysis
• Neurologic abnormalities may resolve slowly
• Chronic encephalopathy can require weeks or longer for recovery

Case literature documents recovery after severe bismuth-associated neurologic and renal toxicity, although persistent renal injury has also occurred.

Important Pitfalls

1. Forgetting the salicylate component

With bismuth subsalicylate, toxicity may actually be predominantly salicylate poisoning.

Always consider a salicylate level in a symptomatic patient.

2. Missing chronic OTC use

Patients may not consider products such as Pepto-Bismol to be “medications.”

Ask specifically about:

• OTC diarrhea remedies
• Dyspepsia preparations
• Duration and frequency of use

3. Misinterpreting black stool

Bismuth commonly causes harmless blackening of the stool and tongue.

However, true GI bleeding must still be excluded when clinically appropriate.

4. Missing renal impairment

Reduced renal function increases the risk of accumulation and severe bismuth toxicity.

5. Using ipecac

Ipecac-induced vomiting is obsolete and should not be used.

6. Assuming chelation is routinely indicated

Evidence supporting chelation in bismuth poisoning is limited.

Treatment is primarily withdrawal of exposure and supportive care.

High-Yield Toxicology Pearls

Bismuth toxicity = chronic encephalopathy + renal injury

With bismuth subsalicylate, also think:

SALICYLATE TOXICITY

Key points:

• Poisoning is uncommon
• Significant toxicity usually follows large or prolonged exposure
• Chronic toxicity may cause encephalopathy
• Acute large exposures may produce acute kidney injury
• Renal impairment increases toxicity risk
• Bismuth levels may confirm exposure but correlate poorly with severity
• Bismuth subsalicylate can cause clinically important salicylate poisoning
• Check a serum salicylate level in symptomatic bismuth-subsalicylate exposure
• Tinnitus is an important clue to salicylate toxicity
• Black tongue and stool are common and usually benign
• Severe salicylate toxicity requires sodium bicarbonate ± hemodialysis
• No universally accepted bismuth antidote exists
• Chelation is not routine
• Do not induce vomiting
• Children and teenagers with influenza-like illness or chickenpox should not receive bismuth subsalicylate because of the risk of Reye syndrome